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I. Study details 
1. 1958 Birth cohort (1958BC) 
Data collection: 1958BC includes all births during one week in March in England, Scotland and Wales.1 
Participants in the study have been followed regularly with information collected on a wide-range of factors 
related to health, lifestyle, growth and development. At age 44-45y (August 2002 to March 2004) cohort 
members were invited to a biomedical survey, which included measurement of weights and heights from 9,348 
participants. 8,432 cohort members consented to genetic studies, of whom 7,414 also had information on serum 
25(OH)D concentrations and BMI.  
Measurement of serum 25(OH)D: Serum 25(OH)D concentrations were measured using automated application 
of the IDS OCTEIA ELISA on the Dade-Behring BEP2000 analyzer (sensitivity of 5.0nmol/L, linearity 
≤155nmol/L, and intra-assay CV 5.5-7.2%), with adjustment according to the mean of the Vitamin D External 
Quality Assessment Scheme.2   
Measurement of clinical parameters: Weight and standing height (n= 9,348) were measured without shoes and 
in light clothing by a trained nurse. Body mass index was calculated as weight (kg)/height (m)2. Three blood 
pressure measurements were taken with the participant seated for at least 5 minutes using an Omron 705CP 
automated digital oscillometric sphygmomanometer (Omron, Tokyo, Japan). A large cuff was used if the mid-
upper arm circumference was ≥32 cm. Measures deemed invalid by the nurse were excluded and an average of 
the remaining values was used in analyses. Non-fasting venous blood samples were analysed for total 
cholesterol and triglyceride levels by an autoanalyser (Olympus AU640, Japan) using enzymatic methods. 
Genotyping: 3,000 DNA samples were selected as control subjects in the Welcome Trust Case Control 
Consortium 2 (WTCCC2). This includes an initial 1,500 sampled in the first round of WTCCC. The samples 
were genotyped on the Affymetrix 6.0 platform and the genotype calling algorithm was Chiamo.3 Sample 
exclusions included relatedness, exceeding the heterozygosity thresholds, non-European ancestry, gender 
discrepancy, outlying allele intensities from a selection of SNPS compared to the larger sample and discordance 
with external genotyping. The SNP exclusions were done for MAF < 1%, statistical information from the 
genotyping call < 0.975, Hardy-Weinberg equilibrium (HWE) p-value < 1e-20, SNP missingness > 0.02 and 
gene-chip plate association 1e-5. An additional 2500 participants were genotyped by the Type 1 Diabetes 
Genetics Consortium on the Illumina 550K Infinium platform and the genotyping calling algorithm was 
Illuminus.4 Sample exclusions were done on sample call rate > 3%, exceeding the heterozygosity thresholds, 
gender discrepancy and non-European ancestry. The SNP exclusions were done for MAF < 1%, HWE p-value < 
1e-7 and SNP call rate <95%. The vitamin D SNPs were genotyped using the Taqman platform (Applied 
Biosystems, Warrington, UK). 
 
2. CROATIA-Korcula 
Data collection: The CROATIA-Korcula study, Croatia, is a family-based, cross-sectional study in the isolated 
island of Korcula that included 965 examinees aged 18-95. Blood samples were collected in 2007 along with 
many clinical and biochemical measures and lifestyle and health questionnaires.  
Measurement of clinical parameters: Blood pressure was measured using standard procedures. Briefly, the 
subject was seated in a quiet room. Following 5 minutes of rest, blood pressure was recorded twice during the 
examination and the mean of the two readings was used for the analyses. Weight and standing height were 
measured without shoes and in light clothing by a trained research nurse using scales and stadiometer. Body 
mass index was calculated as kg/m2. Fasting venous blood samples were analysed for total cholesterol and 
triglyceride levels. 
Genotyping: The CROATIA-Korcula study genotyping used the Illumina HAP370CNV SNP chip.  Genotype 
quality control excluded SNPs with a call rate <98%, MAF <0.01, HWE p<10e-6.  Analysis was performed 
using GenABEL with first 3 principal components accounting for population stratification. SNPs were imputed 
to HapMap22, build 36, using MACHv1.16 and GenABEL derived residuals were analysed using ProbABEL. 
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3. CROATIA-Split 
Data collection: The CROATIA-Split study, Croatia, is an on-going population-based, cross-sectional study in 
the Dalmatian City of Split that so far includes 535 examinees aged 18-95. Blood samples were collected in 
2009 along with many clinical and biochemical measures and lifestyle and health questionnaires.  
Measurement of clinical parameters: Blood pressure was measured using standard procedures. Briefly, the 
subject was seated in a quiet room. Following 5 minutes of rest, blood pressure was recorded twice during the 
examination and the mean of the two readings was used for the analyses. Weight and standing height were 
measured without shoes and in light clothing by a trained research nurse using scales and stadiometer. Body 
mass index was calculated as kg/m2. Fasting venous blood samples were analysed for total cholesterol and 
triglyceride levels. 
Genotyping: The CROATIA-Split study genotyping used the Illumina HAP370CNV SNP chip.  Genotype 
quality control excluded SNPs with a call rate <98%, MAF <0.01, HWE p<10e-6.  Analysis was performed 
using GenABEL with first 3 principal components accounting for population stratification. SNPs were imputed 
to HapMap22, build 36, using MACHv1.16 and GenABEL derived residuals were analysed using ProbABEL. 
 
4. CROATIA-Vis 
Data collection: The CROATIA-Vis study, Croatia, is a family-based, cross-sectional study in the isolated 
island of Vis that included 1,056 examinees aged 18-93. Blood samples were collected in 2003 and 2004 along 
with many clinical and biochemical measures and lifestyle and health questionnaires. 
Measurement of clinical parameters: Blood pressure was measured using standard procedures. Briefly, the 
subject was seated in a quiet room. Following 5 minutes of rest, blood pressure was recorded twice during the 
examination and the mean of the two readings was used for the analyses. Weight and standing height were 
measured without shoes and in light clothing by a trained research nurse using scales and stadiometer. Body 
mass index was calculated as kg/m2. Fasting venous blood samples were analysed for total cholesterol and 
triglyceride levels. 
Genotyping: The CROATIA-Vis study genotyping used the Illumina HAP300v1 SNP chip.  Genotype quality 
control excluded SNPs with a call rate <95%, MAF <0.01, HWE p<10e-6 .  Analysis was performed using 
GenABEL with first 3 principal components accounting for population stratification. SNPs were imputed to 
HapMap22, build 36, using MACHv1.16.  and GenABEL derived residuals were  analysed using ProbABEL. 
5. Danish Osteoporosis Prevention Study (DOPS)  
Data collection: The study included 2016 participants recruited by direct mailing to a random sample 
(n=47,720) of 45–58 years old peri- or postmenopausal Danish women.5 Inclusion criteria were: (1) Women 
with intact uterus aged 45–58 years and 3–24 months past last menstrual bleeding or experiencing 
perimenopausal symptoms (including irregular menstruations)—the latter combined with elevated serum 
follicular stimulating hormone (FSH), and (2) Hysterectomised women aged 45–52 years and having elevated 
FSH. Exclusion criteria were: (a) Metabolic bone disease, including osteoporosis defined as non-traumatic 
vertebral fractures on X-ray; (b) Current oestrogen use or oestrogen use within the past 3 months; (c) Current or 
past treatment with glucocorticoids >6 months; (d) Current or past malignancy; (e) Newly diagnosed or 
uncontrolled chronic disease; (f) Alcohol or drug addiction. Among included women, 1,716 accepted to donate a 
blood sample for DNA analyses. Women were included at four different study centers. 
Measurement of serum 25(OH)D: All plasma 25OHD analyses were performed at the same lab using a 
competitive assay using rachitic rat binding protein measuring both vitamins D2 and D3 (Lund, B. & Sorensen, 
O.H. Measurement of 25-hydroxyvitamin D in serum and its relation to sunshine, age and vitamin D intake in 
the Danish population. Scandinavian Journal of Clinical Laboratory Investigations, 1979; 39, 23–30).  The 
lower detection limit was 12,5 nmol/l. The intra- and interassay precisions were 8% and 10%, respectively. 
Measurement of clinical parameters: Blood pressure was measured manually using a sphygmomanometer, with 
the participant in the recumbent position after 5 minuts of rest . All blood pressure measurements were 
performed in the morning. Women were classify as having hypertension using the following algorithm: a) 
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Measured blood pressure has been adjusted in user of blood pressure lowering drugs by adding 15 mmHg  to 
SBP and 10 mmHg to DBP; b) Women have been classified as having hypertension if the reported use of blood 
pressure lowering drugs due to a diagnosis of hypertension or if they had an adjusted systolic blood pressure 
≥140 mmHg, or an adjusted diastolic blood pressure ≥90 mmHg. Weight and standing height were measured 
without shoes and in light clothing by a study Investigator. Body mass index was calculated as weight 
(kg)/height(m2).  Non-fasting venous blood samples were analysed for total cholesterol and triglyceride levels 
by standard laboratory methods.  
Genotyping: All genotyping was outsourced to KBiosciences who employ a novel form of competitive allele 
specific PCR (KASPar) system for genotyping. The SNP exclusions were done for MAF < 1%, statistical 
information from the genotyping call < 90%, HWE p-value < 0.01 and SNP missingness > 0.01.  
 
6. Diabetes Prevention Program (DPP)  
Data collection: The DPP enrolled 3,819 US adult (age ≥25 years) participants of multiple ethnicities with high 
risk criteria for the development of diabetes: overweight, elevated fasting glucose, and impaired glucose 
tolerance.6 Of these participants, 3,234 were randomized to placebo, metformin 850 mg twice daily, or lifestyle 
intervention with a goal weight loss of ≥7% and ≥150 minutes of physical activity per week.  A fourth 
troglitazone treatment arm (585 participants) was terminated early due to concerns for drug-related 
hepatotoxicity. 3,541 DPP participants consented to genetic investigation of whom 1899 had information on 
serum 25(OH)D concentrations. For the purposes of this study, 1083 individuals of European Ancestry (self-
reported ethnicity of white or Caucasian) were examined for the vitamin D-related genetic variants and baseline 
blood pressure.  
Measurement of serum 25(OH)D: Baseline total 25-hydroxyvitamin D levels were measured by liquid 
chromatography, tandem mass spectrometry (LC/MS/MS) (Waters ACQUITY UPLC with TQD triple 
quadruple mass spectrometer), certified through the national Institute of Standards and Technology (NIST) 
vitamin D quality assurance program.  
Measurement of clinical parameters: BMI was measured by dividing weight in kilograms by the square of the 
standing height in meters.  Blood pressure was measured on the upper arm with an appropriately sized cuff for 
arm size.  The mean of two blood pressure measurements was used.  Hypertension was defined according to 
World Health Organization guidelines as systolic blood pressure ≥140 mmHg, or diastolic blood pressure ≥90 
mmHg, or current antihypertensive medication. Fasting total cholesterol and triglycerides were measured.  
Measurements of total plasma cholesterol and triglycerides were performed enzymatically on a chemistry 
autoanalyzer by using methods standardized to the Centers for Disease Control and Prevention reference 
methods. We obtained HDL fractions for cholesterol analysis by treating whole plasma with dextran sulfate 
magnesium chloride to precipitate all of the apolipoprotein B–containing lipoproteins. We calculated low-
density lipoprotein cholesterol by using the Friedewald equation. In participants with triglyceride levels higher 
than 4.5 mmol/L (>400 mg/dL), the lipoprotein fractions were separated by using preparative ultracentrifugation 
of plasma by beta quantification.   
Genotyping: A total of 4 vitamin D-related SNPs were genotyped in 3,541 DPP participants using the iPLEX-
GOLD assay from Sequenom.  SNPs were excluded based on the following thresholds: call rate <95%, or failed 
Hardy-Weinberg equilibrium with a P<0.001 in at least 1 ethnic group.  
 
7. Edinburgh Artery Study (EAS) 
Data collection: The EAS is a prospective study of 1592 European descent individuals (809 men and 783 
women) aged 55 to 74 years enrolled in 1988.7 Individuals were randomly selected from 11 general practices 
serving a range of socioeconomic and geographic areas throughout the city of Edinburgh. Participants 
completed a self-administered questionnaire at baseline and at 5 and 12 years of follow-up that included 
demographical and lifestyle variables, the WHO angina and intermittent claudication questionnaires. Individuals 
were also invited for a clinical examination at baseline and at 5 and 12 years after enrolment. 
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Measurement of clinical parameters: Standing height (without shoes) was measured to the nearest 5 mm with 
the use of a free-standing metal ruler on a heavy base. Weight (without shoes and outer clothing) was measured 
to the nearest 100 g on digital scales (Soehnle). Body mass index (BMI) was calculated as the weight in 
kilograms divided by square of the height in meters. Systolic and diastolic (phase V) blood pressures were 
recorded in the right arm only, after 10 minutes of rest with the patient in the supine position, with a Hawksley 
random zero sphygmomanometer. At baseline, a fasting 20-mL sample of venous blood was taken for 
estimation of biochemical, inflammatory, and hemostatic factors. Tests for serum total cholesterol, HDL 
cholesterol, and triglycerides were performed on a Cobas Bio analyzer (Roche Products) with standard kits. 
Genotyping: DNA was extracted from 1007 participants attending the 5 year follow up examination. The 
genotyping was done through KBiosciences. The call rates were >95% and the HWE p values were > 0.18. 
 
8. English Longitudinal Study of Ageing (ELSA) 
Data collection: ELSA is a follow-up study of respondents to the UK Government's Health Survey for England 
(HSE) (at http://www.dh.gov.uk/), an annual cross-sectional survey designed to be representative of the 
community-living population. The ELSA sample included those aged ≥50 years seen originally either in HSE 
1998, 1999 or 2001 with data collected by face-to-face interviewing in respondents’ own homes in 2002 and 
2004. Blood samples were taken for DNA analysis from those respondents who were willing and eligible to 
donate samples during a nurse visit following the 2004 questionnaire. There were 9432 interviewed respondents 
in ELSA 2004, of which 7666 volunteered for the nurse-led clinical visit, during which 6231 donated blood 
specimens. 
Measurement of clinical parameters: Height, weight, and WC were measured during the nurse visit. Height 
without shoes was measured using a portable stadiometer. One measurement was taken with the informants 
stretching to the maximum height and the head in the Frankfort plane. Weight was measured using a portable 
electronic scale. Informants were asked to remove their shoes and any bulky clothing. For 14 informants 
weighing >130 kg, we used their estimated weights because the scales are inaccurate above this level. BMI is 
defined as weight (kg)/height (m2) (ranged from 14.9 to 56.2 kg/m2). WC was defined as the midpoint between 
the lower rib and the upper margin of the iliac crest. Two measurements were taken using a tape with an 
insertion buckle at one end. Circumference was recorded to the nearest even millimetre and if the two 
measurements differed by >3 cm one-third was taken. The mean values of the two valid measurements (the two 
that were the closest to each other, if there were three measurements) used in the analyses.   Blood pressure 
measurements were taken using an OMRON HEM-907 blood pressure monitor by a nurse.  Three 
measurements in the seated position following 10 minutes of rest were taken.  Heavy physical activity, smoking, 
and alcohol use were avoided for 30 minutes prior to recording the blood pressure measurement, the average of 
3 measures were used in the analysis.  Blood samples were collected and transported to the laboratory by post.   
Genotyping: We extracted DNA from blood samples by using magnetic bead technology (Medical Solutions, 
Nottingham). Genotyping was performed using the KASPar methodology.  The call rates and the concordance 
rates of the four SNPs were >98%. The HWE p values were P>0.08.   
 
9. ESTHER 
Data collection: ESTHER is a large population-based cohort study (ESTHER = “Epidemiologische Studie zu 
Chancen der Verhütung, Früherkennung und optimierten Therapie chronischer Erkrankungen in der älteren 
Bevölkerung”) conducted in Saarland, Germany. Briefly, baseline recruitment was done in Saarland, Germany. 
Between July 2000 and December 2002 and included 9949 participants aged between 50 and 74 years. A 
standardized health questionnaire on sociodemographic, medical, and lifestyle factors was completed by each 
participant. Vital status of all participants was ascertained via local population registry of the Saarland through 
the end of 2010. Causes of death were verified by death certificates and coded based on ICD-10 classifications. 
The study was approved by the ethics committees of the medical faculty of the University of Heidelberg and of 
the medical board of the state of Saarland. Written informed consent was obtained from each participant. 
Measurement of serum 25(OH)D: Baseline serum levels of 25(OH)D were measured for women and men in the 
framework of two different projects with the DiaSorin-Liason (Diasorin, Inc., Stillwater, USA) and the IDS-
5 
 
iSYS (Immunodiagnostic Systems GmbH, Frankfurt Main, Germany) immunoassay in 2006 and 2010, 
respectively. All obtained 25(OH)D values were retrospectively standardized with liquid chromatography 
tandem-mass spectrometry (LC-MS/MS) in the Department of Clinical Chemistry, Canisius Wilhelma Hospital, 
Nijmegen, The Netherlands, as described previously.8 
Measurement of clinical parameters: Height, weight and systolic blood pressure were assessed and documented 
on a standardized form by the general practitioners during the health check-up. Total cholesterol and 
triglycerides were measured from serum samples by standard high performance liquid chromatography methods 
in the central laboratory of the University Clinics of Heidelberg.9   
Genotyping:  The samples were genotyped using the TaqMan OpenArrayTM SNP Genotyping Platform (Applied 
Biosystems, Foster City, CA) according to the manufacturer’s instructions.  The overall call rate was 97.3%.  
The genotyping concordance was 100%. 
 
10. Framingham Heart Study (FHS) 
 
Data collection: The FHS consists of three cohorts. The original cohort was recruited in 1948 and includes 
5,209 participants from Framingham, Massachusetts, US.10  Clinical exams were conducted every other year to 
investigate cardiovascular disease and related risk factors. The Offspring cohort is comprised of 5,124 children 
of the Original cohort and the children's spouses. They were recruited in 1971, and have undergone 
examinations roughly every four years. A total 4,095 children of the Offspring cohort form the Third Generation 
cohort were enrolled in 2002. The current study sample consists of 1,815 individuals from the Offspring 
Generation who attended the 5th examination (1991-1995) and 3,841 from the Third Generation who attended 
the 1st examination (2002-2005). 
Measurement of serum 25(OH)D: 25(OH)D was determined by a competitive protein-binding assay. Intra-assay 
CV for this assay was 7%.  
Measurement of clinical parameters: BMI was derived as weight (in kilograms) divided by the square of height 
(in meters). Blood pressure was measured twice at rest using a mercury column sphygmomanometer by a 
physician, and the average from these two measures was taken. Lipid profiles were measured from morning 
fasting blood samples with standardized assays. 
Genotyping: Genotyping was performed using the Affymetrix 500K SNP arrays supplemented with the MIPS 
50K array.  Samples were excluded if they had call rate < 97%, excess Mendelian errors (> 1000) or average 
heterozygosity outside of 5 SD of mean (< 25.758% or > 29.958%).   
 
11. Gothenburg Osteoporosis and Obesity Determinants (GOOD) Study:  
Data collection: The Gothenburg Osteoporosis and Obesity Determinants (GOOD) study was initiated to 
determine both environmental and genetic factors involved in the regulation of bone and fat mass.11 Male study 
participants were randomly identified in the greater Gothenburg area in Sweden using national population 
registers, contacted by telephone, and invited to participate. To be enrolled in the GOOD study, participants had 
to be between 18 and 20 years of age. There were no other exclusion criteria, and 49% of the study candidates 
agreed to participate. A total of 921 individuals were included for the present study.  
Measurement of serum 25(OH)D: Serum levels of 25-hydroxyvitamin D were measured by radioimmunoassay  
(DiaSorin Inc, Stillwater, MN) (n = 921). Intra-assay CV was 6%. 
Measurement of clinical parameters: Height was measured using a wall-mounted stadiometer, and weight was 
measured to the nearest 0.1 kg. Body mass index was calculated as weight (kg)/height (m2). Diastolic and 
systolic blood pressure was measured with a Omron 705CP after a 5 min rest. Measurements were performed 
(once) on the right arm after a 5 min rest with the subject lying down. 
Genotyping: Genotyping was performed with Illumina HumanHap610 arrays at the Genetic Laboratory, 
Department of Internal Medicine, Erasmus Medical Center, Rotterdam, the Netherlands. Genotypes were called 
using the BeadStudio calling algorithm. Genotypes from 938 individuals passed the sample quality control 
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criteria [exclusion criteria: sample call rate <97.5%, gender discrepancy with genetic data from X-linked 
markers, excess autosomal heterozygosity >0.33 (~FDR < 0.1%), duplicates and/or first degree relatives 
identified using IBS probabilities (>97%), ethnic outliers (3 SD away from the population mean) using multi-
dimensional scaling analysis with four principal components]. We sequentially discarded intensity-only markers 
and markers with a SNP call rate <95%.  
 
12. Health2000 GenMets (GENMETS) Study 
  
Data collection: The GENMETS sample is a subset of 2,212 individuals of the Health2000 study9 collected as 
metabolic syndrome cases and their matched controls. The health 2000 survey was conducted in 2000 and 2001 
in Finland. The survey included an interview on medical history, health-related lifestyle habits, and a clinical 
examination where a blood sample was drawn. For the present study, a total of 868 controls with genotype data, 
BMI and vitamin D measurements were included.  
Measurement of serum 25(OH)D: Serum 25(OH)D concentrations were measured using 25-hydroxy Vitamin D 
RIA kit method (DiaSorin, Stillwater, MN, USA). The intra-assay coefficient of variation (CV) was 3,5 % and 
the interassay CV was 6.9 % at the concentration of 36 nmol/l. The limit of detection was 3,5 nmol/l. The serum 
specimens were stored frozen at - 70 C until analysed and protected from light when processed.  
Measurement of clinical parameters: BMI was calculated as weight (kg)/height (m2) using height and weight 
data from all possible sources [weight: self-reported weight and measured weight (digital scale or bioimpedance 
device); height: self-reported and measured height with wall-mounted stadiometer]. Blood pressures were 
measured after the subjects had been seated quietly in the measurement room for at least five minutes with 
standard mercury manometer (Mercuro 300; Speidel & Keller, Jungingen, Germany). Blood samples were 
analysed for total cholesterol and triglyceride levels by Olympus AU400 (Germany). 
Genotyping: Genotyping was done on Illumina 610K arrays. 598,203 SNPs were successfully called with 
Illuminus software. Sample exclusions included sample call rate (<95%), relatedness, heterozygosity and gender 
discrepancy. The SNP exclusions were done for MAF < 1%, call rate < 95%, SNP clustering probability for 
each genotype < 95%, HWE p < 1x10-6. 
 
13. Health, Aging and Body Composition (Health ABC) Study  
Data collection: The Health ABC study is a prospective cohort study investigating the associations between 
body composition, weight-related health conditions, and incident functional limitation in older adults.12 Health 
ABC enrolled well-functioning, community-dwelling black (n=1,281) and white (n=1,794) men and women 
aged 70-79 years between April 1997 and June 1998.  Participants were recruited from a random sample of 
white and all black Medicare eligible residents in the Pittsburgh, PA, and Memphis, TN, metropolitan areas in 
the United States. Participants have undergone annual exams and semi-annual phone interviews. The current 
study sample consists of 1,558 white participants who attended the second exam in 1998-1999 with available 
genotyping and serum 25(OH)D concentrations.   
Measurement of serum 25(OH)D: Serum 25(OH)D concentrations were measured using fasting blood samples 
collected in the morning after a 12-hour fast, centrifuged, and stored at -80° C. Serum 25(OH)D was measured 
using a 2-step radioimmunoassay (25-Hydroxyvitamin D 125I RIA Kit, DiaSorin, Stillwater, Minn., USA).  The 
inter- and intra-assay coefficients of variation for serum 25(OH)D were 6.78% and 9.16%, respectively.  
Measurement of clinical parameters: Weight without shoes or heavy jewellery and wearing a standard clinic 
gown was measured in kilograms using a standard balance beam scale. Height without shoes was measured in 
millimetres using a Harpenden stadiometer (Holtain Ltd., Crosswell, United Kingdom).  Body mass index was 
calculated as weight (in kg) / height (in m) squared. Two blood pressure measurements were taken with the 
participant seated for at least 5 minutes using a conventional mercury sphygmomanometer and averaged. Total 
cholesterol and triglycerides were determined by a colorimetric technique on a Vitros 950 analyzer (Johnson & 
Johnson, New Brunswick, NJ) after an overnight fast.  
Genotyping: Genotyping was performed by the Center for Inherited Disease Research (CIDR) using the 
Illumina Human1M-Duo BeadChip system.  Samples were excluded from the dataset for the reasons of sample 
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failure, genotypic sex mismatch, and first-degree relative of an included individual based on genotype data.  
Genotyping was successful in 1663 Caucasians.  Analysis was restricted to SNPs with minor allele frequency ≥ 
1%, call rate ≥97% and HWE p≥10-6. Genotypes were available on 914,263 high quality SNPs for imputation 
based on the HapMap CEU (release 22, build 36) using the MACH software (version 1.0.16).   
 
14. Helsinki Birth Cohort Study (HBCS) 
Data collection: HBCS is composed of 13,345 individuals born between the years 1934-44 in one of the two 
main maternity hospitals in Helsinki, Finland.13  Between 2001 and 2003, a randomly selected sample of 928 
males and 1,075 females participated in a clinical follow-up study with a focus on cardiovascular, metabolic and 
reproductive health, cognitive function and depressive symptoms. After quality control, genome-wide 
association (GWA) data is available in 1728 of the participants. Detailed information on the selection of the 
HBCS participants and on the study design can be found elsewhere. Research plan of the HBCS was approved 
by the Institutional Review Board of the National Public Health Institute and all participants have signed an 
informed consent. 
Measurement of clinical parameters: Weight and standing height were measured without shoes and in light 
clothing by a trained nurse.  Body mass index was calculated as weight (kg)/height(m)2. Serum total and HDL 
cholesterol and triglyceride concentrations were measured using standard enzymatic methods. Blood pressure 
was measured from the right arm while the subject was in the sitting position and was recorded as the mean of 
two successive readings from a standard sphygmomanometer.  
Genotyping: DNA was extracted from blood samples and genotyping was performed with a modified Illumina 
610k chip by the Wellcome Trust Sanger Institute, Cambridge, UK. Relatedness of the participants was 
examined with the pair-wise IBD estimates and closely related individuals were excluded from the analyses. 
None of the participants showed non-European ancestry. Moreover, participants with X-chromosomal genotypes 
discrepant with the reported sex were removed. After quality control procedures 1720 samples remained for the 
analyses. SNPs were included in the analyses if they met the following conditions: call rate ≥ 0.95, minor allele 
frequency ≥ 0.01, and HWE test with P ≥1x10-5. Genomic coverage was extended to ~2.5M common SNPs by 
imputation using the HapMap phase II CEU data (NCBI build 36 (UCSC hg18)) as the reference sample and 
MACH software. SNPs with low imputation quality (r-squared < 0.30), low minor allele frequency (MAF < 
.01), or that diverged from HWE (1x10-5), were excluded from the analyses. 
 
15. Hertfordshire cohort study (HCS) 
 
Data collection: The Hertfordshire Cohort Study (HCS) has recruited 3000 men and women born in 
Hertfordshire UK during 1931-9 and still living there in adult life.14  Participants in the study have been 
followed regularly with information collected on a wide range of factors related to health, lifestyle and infant 
growth. During 1998-2003 cohort members attended a research clinic, which included anthropometric data 
collection and blood sampling for genetic studies and serum 25(OH)D concentration. Full informed consent was 
obtained. In total, the present study included 2,997 individuals.  
Measurement of serum 25(OH)D: Automated DiaSorin chemiluminescent assay (CV 10-12% within batch, and 
10-15% between batch) was used to measure 25(OH)D. 
Measurement of clinical parameters: Height was measured to the nearest 0.1cm using a Harpenden pocket 
stadiometer; weight was measured to the nearest 0.1kg on a SECA floor scale. Serum total and HDL cholesterol 
and triglyceride concentrations were measured using standard enzymatic methods.  Blood pressure was 
measured from the right arm while the subject was in the sitting position and was recorded as the mean of two 
successive readings from a standard sphygmomanometer.   
Genotyping: Genotyping was performed using TaqMan SNP genotyping assays (Applied Biosystems, 
Warrington, UK) according to the manufacturer’s protocol. Genotype frequencies were in HWE (p>0.01). Call 
rates were >98%. 100% concordances of duplicates (n=300) were observed. 
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16. InCHIANTI study  
 
Data collection: InCHIANTI is performed in two sites: Greve in Chianti (Area1; 11,709 inhabitants; >65 years: 
19.3%) and Bagno a Ripoli (Village of Antella, Area2, 4704 inhabitants; >65 years: 20.3%). The data collection 
started in September 1998 and was completed in March 2003. 3 and 6-year follow-up assessment of the 
InCHIANTI study population were performed in the years 2001-2003 and 2004-2006. A nine-year follow-up is 
already planned. Interviews were conducted at the participants' homes. The participants signed an unformed 
participation consent that included permission to consult past and future administrative databases and medical 
charts, and conduct analyses on the blood cells, DNA and urine samples stored in the study biological bank. 
Participants came to study clinic for blood drawing tests, having fasted at least 8 and just concluded 24-hour 
urine collection. The participants received also a series of examinations including: a 5-slice peripheral 
quantitative computed tomography (pQCT), a surface electroneurography assessing nerve conduction velocity 
od the right peroneal nerve, a standard electrocardiogram, an ultrasound colour doppler examination of the 
carotid and vertebral arteries and of the veins of the lower limbs, and an assessments of the ankle-brachial index. 
On the second appointment a clinical evaluation and a comprehensive motor and cognitive performances session 
were performed.  
Measurement of serum 25(OH)D: Serum levels of vitamin D (25OHD) were measured by radioimmunoassay 
(RIA kit; DiaSorin, Stillwater, MN). The intra-assay and inter-assay coefficients of variation for vitamin D were 
8.1% and 10.2%, respectively.  
Measurement of clinical parameters: Height and weight were measured at the study clinic, and BMI was 
calculated as weight (in kg) divided by the square of height (in m). Morning, fasting blood samples were 
collected after a 15-minute resting. Three blood pressure measurements were taken with the participant seated 
for at least 5 minutes using an Omron 705CP automated digital oscillometric sphygmomanometer (Omron, 
Tokyo, Japan). A large cuff was used if the mid-upper arm circumference was =32 cm. Measures deemed 
invalid by the nurse were excluded and an average of the remaining values was used in analyses. Total 
cholesterol and triglyceride levels were determined by commercial assays (Roche Diagnostics, Mannheim, 
Germany). 
Genotyping: Genome-wide genotyping was performed using the Illumina Infinium HumanHap550 genotyping 
chip (ver1 and ver3 chips were used).15 This product assays 550,000 unique SNPs derived primarily from staged 
I and II of the International Haplotype Map Project (www.HapMap.org). Experiments were performed as per the 
manufactures instructions using 750 ng of genomic DNA extracted from whole blood. After processing chips 
were scanned on Illumina BeadStation scanners. All data were analyzed in BeadStudio (version 3; Illumina), 
genotype calls were made using the standard cluster files provisded by Illumina. Samples were initlay assessed 
for genotype success rare (98%) and concordance of reported and genotype gender. Nine samples were removed 
from further analysis due to gender mismatch. Eighty seven samples failed the cut off genotype success rate of 
98%; forty eight of these samples were re-purified and successfully genotyped, thus in total 48 samples were 
removed from further analysis.  
 
17. LifeLines Cohort Study 
Data collection: LifeLines is a multi-disciplinary prospective population-based cohort study examining in a 
unique three-generation design the health and health-related behaviours of 165,000 persons living in the North 
East region of The Netherlands. It employs a broad range of investigative procedures in assessing the 
biomedical, socio-demographic, behavioural, physical and psychological factors which contribute to the health 
and disease of the general population, with a special focus on multimorbidity and complex genetics. Both are 
community based cohort studies from the northern part of the Netherlands and have been approved by the 
review board of the University Medical Center Groningen. This study adheres to the principles expressed in the 
Declaration of Helsinki. All subjects provided written informed consent. 
Measurement of clinical parameters:  Height, weight, and WC were measured during the nurse visit without 
shoes and in light clothing. Body mass index was calculated as weight (kg)/height (m)2. The measurement of 
serum cholesterol and triglycerides was performed using homogenous enzymatic colorimetric methods 
according to the manufactures instructions (Roche Diagnostics). Blood pressure has been measured using 
DINAMAP. 
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Genotyping:  Genotyping for Lifelines was performed on the Illumina CytoSNP12 v2 chip. Samples were 
excluded based on call rates below 0.95, gender mismatch, duplicate discordance and genetic similarity. 
Population stratification was assessed by principal component analysis (PCA) over the sample correlation 
matrix, based on 16,842 independent (LD-pruned) SNPs.  Samples were excluded when for they diverged from 
the mean with at least 3 standard deviations (Z-score > 3) for the first 5 principal components. SNPs were 
excluded with a minor allele frequency of <0.01, call rate <0.95, or deviation from Hardy Weinberg equilibrium 
(P < 1 × 10-5). Genome wide genotype imputation was performed using Beagle v. 3.1.0, using the NCBI build 
36 of Phase II HapMap CEU data (release 22) as reference panel.  
 
18. Lifestyle- Imune System- Allergy plus environment and genetics study (LISAplus) and German Infant 
Study on the influence of Nutrition Intervention plus environment and genetics (GINIplus) 
Data collection: The influence of Life-style factors on the development of the Immune System and Allergies in 
East and West Germany PLUS the influence of traffic emissions and genetics (LISAplus) Study and the German 
Infant study on the influence of Nutrition Intervention PLUS environmental and genetic influences on allergy 
development (GINIplus) are population based birth cohort studies conducted in Germany.16 A total of 9088 
healthy, mature (gestational age over 37 weeks) neonates with a birth weight over 2500g were recruited between 
1995 and 1999. Children in the studies have been followed regularly. Height and Weight was measured during a 
clinical examination at age 10 years. Genetic information and valid blood pressure measurements were available 
for 901 children, of whom 848 had also information on serum 25 (OH)D concentrations.   
Measurement of serum 25(OH)D: Serum levels of vitamin D (25OHD) were measured on the fully automated 
Modular system E170, Roche Diagnostics, Mannheim, Germany (intra-assay CV 2.2-6.8%, inter-assay CV 4.9-
11.9%). 
Measurement of clinical parameters: Weight and standing height were measured without shoes and in light 
clothing by a study physician. Body mass index was calculated as weight (kg)/height(m)2. Blood pressure was 
measured twice in a sitting position from the right arm after 5 min of rest during the clinical examination at the 
study centres. Invalid measures were excluded and the second measurement was used. The measurement of 
serum cholesterol and triglycerides was performed using homogenous enzymatic colorimetric methods 
according to the manufactures instructions (Roche Diagnostics GmbH Mannheim). All parameters and controls 
were analysed on a Modular Analytics System from Roche Diagnostics GmbH Mannheim. External controls 
were used in accordance with the guidelines of the German Society of Clinical Chemistry and Laboratory 
Medicine. 
Genotyping: Individual DNA was analyzed using the Affymetrix Human SNP Array 5.0 and 6.0. Genotypes 
were called using BRLMM-P algorithm (5.0), respectively BIRDSEED V2 algorithm (6.0), imputed after 
quality control (MAF>1%, HWE>1e-05, heterozygosity 4SD, call rate per SNP and person >95%) in 
IMPUTE2.  
 
19. Ludwigshafen Risk and Cardiovascular Health (LURIC) Study 
 
Data collection: The LURIC Study is a prospective cohort study among 3,316 study participants who were 
routinely referred to a tertiary care medical centre in south-west Germany between 1997 and 2000.17 Inclusion 
criteria were the availability of a coronary angiogram, German ancestry and clinical stability with the exception 
of acute coronary syndromes (ACS).  Exclusion criteria were any acute illness other than ACS, any chronic 
disease where non-cardiac disease predominated and a history of malignancy within the past five years. Patients 
were continuously followed up with respect to fatal events. 25(OH)D was measured in 3,299 patients of the 
LURIC study. 
Measurement of serum 25(OH)D: 25(OH)D was measured in serum by means of a radioimmunoassy (RIA) 
(DiaSorin, Antony, France, and Stillwater, MN) with intra- and inter-assay coefficients of variation of 8.6 and 
9.2, respectively.  
Measurement of clinical parameters: Body weight was measured without shoes and in light clothing by a 
trained nurse. Body height was recorded to the nearest centimetre with the subject barefoot and in the upright 
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position. Body mass index was calculated as weight (kg)/height (m)². Body mass index was available in all 
3,316 study participants. Blood pressure was measured with an automated oscillometric device (Omron MX4, 
Omron Healthcare GmbH, Hamburg, Germany) while supine for at least 10 min. At least three consecutive 
measurements of systolic and diastolic blood pressures were taken 30 seconds apart and mean values of these 
measurements are reported. Measurements were considered invalid and repeated if they varied > 10 mmHg 
systolic, > 5 mmHg diastolic, or heart rate > 5 beats per minute from each other (except for atrial fibrillation). 
Total cholesterol and triglycerides were measured enzymatically using WAKO reagents on a WAKO 30R 
analyzer (Neuss, Germany) (Wako). LDL-cholesterol and HDL-cholesterol were measured after separating 
lipoproteins with a combined ultracentrifugation–precipitation method (β-quantification). 
Genotyping: DNA samples of 1,985 patients were genotypes with the Affymetrix Genome-Wide Human SNP 
Array 6.0 (Affymetrix 6.0) and 500K. Samples with low call rate (<90 %), cryptic relatedness or gender 
discrepancy were excluded from analyses. SNP exclusions were done for MAF<1%, HWE <10e-6 and low call 
rate (<95%). 
 
20. Males from Genetics of extremely Overweight Young Adults (GOYA) 
Data collection: The study individuals consist of  randomly selected control group of one in every hundred men 
(n= 3,601) and all extremely overweight men (n= 1,930) which were identified from the records of 362,200 
Caucasian men examined at the mean age of 20 years at the draft boards in Copenhagen and its surroundings 
during the years 1943–77. Standing height and weight were measured at the draft board examinations. All 
extremely overweight men and a random sample of half the men who, were still living in the region, were 
invited to a follow-up survey (anthropometric measurements) in 1992–94 at the mean age of 46 years, at which 
time the blood samples were also taken (753 extremely overweight and 879 control men attended). The criteria 
for invitation to the follow-up surveys and participation have been described elsewhere.18,19 A genome wide 
association study (Genetics of extremely Overweight Young Adults) was carried out recently on the blood 
samples available from the study participants.20 The study was approved by the regional scientific ethics 
committee and by the Danish Data Protection Board. 
Measurement of clinical parameters: Standing height (without shoes) and weight (only in underwears) was 
measured during the draftboard examination by a trained nurse.  The weight was measured on an electronic 
scale (Lindelltronic 8000, Lindell AB, Kristianstad, Sweden). Body mass index was calculated as weight 
(kg)/height(m)2. Blood pressure and pulse were measured automatically with a digital blood pressure meter with 
an appropriate cuff size (model UA 743, A & D, Tokyo, Japan). The final measures were a mean of three 
consecutive measurements, performed with one minute intervals. A large cuff was used if the mid-upper arm 
circumference was ≥32 cm. Measures deemed invalid by the nurse were excluded and an average of the 
remaining values was used in analyses. Non-fasting venous blood samples were analysed for total cholesterol 
and triglyceride levels by an autoanalyser (COBAS MIRA plus: Roche Diagnostic Systems GmbH, Mannheim, 
Germany) using enzymatic methods. 
Genotyping: Of these, 673 extremely overweight and 792 control men were genotyped (and passed quality 
control (QC), 61 failed QC). With a sampling fraction of 0.5% (50% of 1%), these controls represent about 
158,000 men among whom the case group was the most obese. Genome-wide genotyping on the Illumina 610 k 
quad chip was carried out at the Centre National de Genotypage (CNG), Evry, France.20 We excluded SNPs 
with minor allele frequency, <1%, >5% missing genotypes or which failed an exact test of Hardy-Weinberg 
equilibrium (HWE) in the controls. We also excluded any individual who did not cluster with the CEU 
individuals (Utah residents with ancestry from northern and western Europe) in a multidimensional scaling 
analysis seeded with individuals from the International HapMap release 22. We carried out imputation to 
HapMap release 22 (CEU individuals) using Mach 1.0, Markov Chain Haplotyping.21 Other details regarding 
QC of data can be found in the previous report.20 
 
21. MRC National Survey of Health & Development (MRC NSHD) 
Data collection: The Medical Research Council National Survey of Health and Development (MRC NSHD),22 
is an ongoing prospective birth cohort study consisting of a stratified random sample of all births in England, 
Scotland and Wales in one week in March 1946 (http://www.nshd.mrc.ac.uk/). The original cohort comprised 
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2,547 women and 2,815 men who have been followed up over 20 times since their birth. The data collected to 
date include cognitive and physical function, lifestyle and anthropomorphic measures and blood analytes.  At 
age 53 years (1999), 3035 cohort members (1472 men, 1563 women) provided information. The majority 
(n=2989) were interviewed and examined in their own homes by trained research nurses with others completing 
a postal questionnaire (n=46). Of these 2734 consented to genetic studies.  
Measurement of clinical parameters: During the home visits at 53 years, height, weight and blood pressure were 
measured and non-fasting venous blood samples were taken.   Weight and standing height were measured 
without shoes and in light clothing according to a standard protocol; BMI was calculated as weight (kg)/height 
(m)2.  Blood pressure was measured twice, with the survey member seated and after 5 minutes of rest, using an 
Omron HEM-705 automated digital oscillometric sphygmomanometer (Omron); the 2nd blood pressure reading 
was used for this analysis. Survey members were also asked whether they had taken any prescribed medicines or 
tablets for high blood pressure in the last year. Total cholesterol was measured by enzymatic CHOD-PAP.  
Precipitation for measurement of high‐density lipoprotein (HDL) cholesterol was carried out using 
phosphotungstic Mg2+, triglycerides were measured using a glycerol/kinase POD‐linked reaction of glycerol 
liberated enzymatically from triglycerides. All of these measurements were made with a Bayer DAX‐72. 
Low‐density lipoprotein (LDL) cholesterol level was calculated using the Friedewald's formula: LDL 
cholesterol (mmol/l)=total cholesterol−HDL cholesterol–0.45×triglycerides. DNA samples were also collected 
at age 53 years. The data collection received MREC approval, and informed consent was given by respondents 
to each set of questions and measures. 2564 individuals were included in these analyses. 
Genotyping: Genomic DNA was extracted using a modified salting out method (Flowgen, Sittingbourne, UK). 
All genotyping was outsourced to KBiosciences who employ a novel form of competitive allele specific PCR 
(KASPar) system for genotyping. The SNP exclusions were done for MAF < 1%, statistical information from 
the genotyping call < 90%, HWE p-value < 0.01 and SNP missingness > 0.01.  
 
22. Netherlands Study of Depression and Anxiety (NESDA) 
Data collection: NESDA is a multi-centre study23 designed to examine the long-term course and consequences 
of depressive and anxiety disorders (http://www.nesda.nl). NESDA included both individuals with depressive 
and/or anxiety disorders and controls without psychiatric conditions. Inclusion criteria were age 18-65 years and 
self-reported western European ancestry, exclusion criteria were not being fluent in Dutch and having a primary 
diagnosis of another psychiatric condition (psychotic disorder, obsessive compulsive disorder, bipolar disorder, 
or severe substance use disorder).  
Measurement of clinical parameters: Supine BP was measured twice on the right arm with an OMRON device 
(Omron, Tokyo, Japan) and average values of SBP and DBP were calculated. Hypertension was defined 
according to World Health Organization guidelines as systolic blood pressure ≥140 mmHg, or diastolic blood 
pressure ≥90 mmHg, or current antihypertensive medication. Individuals who used antidepressants (not 
serotonin-specific reuptake inhibitors) were excluded from the analyses. Data on vitamin D, cholesterol and 
triglycerides were not available. 
Genotyping: Individual genotyping was conducted by Perlegen Sciences (Mountain View, CA, USA) using a set 
of four proprietary, high-density oligonucleotide arrays as part of the Genetic Association Information Network 
(GAIN).24 Samples failed QC due to uncertain linkage between genotype and phenotype records, evidence of 
contamination, excessive missing genotype data, high genome-wide homozygosity (B75%), first- or second-
degree relationships and non-Caucasian ancestry. SNPs were required not to have any of the following features: 
gross mapping problem, >1 genotype disagreements in 40 duplicated samples, >1 Mendelian inheritance errors 
in complete trio samples, minor allele frequency < 0.01 or > 0.05 missing genotypes. A Hardy–Weinberg filter 
was not used. A total of 435,291 SNPs met these criteria and were included in the final analysis data set.  
 
23. Northern Finland Birth Cohort 1966 (NFBC1966) study 
Data collection: NFBC1966 was originally designed to study factors affecting pre‐term birth, low birth weight 
and subsequent morbidity and mortality.25 Mothers living in the two northern‐most provinces of Finland were 
invited to participate if they had expected delivery dates during 1966. A total of 12,058 live‐births were in the 
study. At age 31 all individuals still living in the Helsinki area or Northern Finland were asked to participate in a 
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detailed biological and medical examination (n=6,007) as well as a questionnaire. Genotype and measured BMI 
data were available on 4,453 individuals in this study with multiple births being excluded.  
Measurement of serum 25(OH)D: Total 25-hydroxyvitamin D was measured with high-performance liquid 
chromatography-tandem mass spectrometry.  
Measurement of clinical parameters: Anthropometric measures, including height, weight and waist 
circumference were measured without shoes and in underwear by a trained nurse. Body mass index was 
calculated as weight (kg)/height (m)2. Systolic and diastolic blood pressures were measured twice with a 
sphygmomanometer with a cuff size of 14 cm x 40 cm in sitting position after 15 minutes of rest. The average of 
the two measurements was used. Blood samples were drawn after overnight fasting. Samples were analysed 
within 24 hours of sampling in the Oulu University Hospital laboratory using on-going internal/external quality 
control. Serum total cholesterol, high-density lipoprotein (HDL)-cholesterol, low-density lipoprotein (LDL)-
cholesterol and triglyceride concentrations were analysed by Hitachi 911 automatic analyzer and commercial 
reagents (Boehringer Mannheim, Germany). 
Genotyping: For NFBC, genomic DNA was extracted from whole blood using standard methods. All DNA 
samples for the Illumina Infinium 370cnvDuo array were prepared for genotyping by the Broad Institute 
Biological Sample Repository (BSP). All individuals in the study were genotyped with call rates >95%. SNPs 
were excluded from analysis if the call rate in the final sample was < 95%, if the P value from a test of HWE 
was <0.0001, or if the MAF was <1%. 
 
24. Northern Finland Birth Cohort 1986 (NFBC 1986) Study 
Data collection: NFBC1986 is a longitudinal one-year birth cohort study from an unselected population. The 
cohort included all the mothers (N = 9,362) with children whose expected date of birth felt between July 1st 
1985 - June 30th 1986 in the two northernmost provinces on Finland (Oulu and Lapland). A small percentage of 
the births occurred towards the end of June 1985 and begin of July 1986. The number of deliveries in the cohort 
was 9 362, which was 99% of all the deliveries taking place in the target period of the cohort. Altogether 9 479 
children were born into the cohort, 9 432 of them live-born. The original data have been supplemented by data 
collected with postal questionnaires at the ages of 7, 8 and 15 / 16 years and various hospital records and 
statistical register data. 
Measurement of clinical parameters: Weight and standing height were measured without shoes and in 
underwear by a trained nurse. Body mass index was calculated as weight (kg)/height (m)2. Systolic and diastolic 
blood pressures were measured in sitting position, after 15 minutes of rest with the cuff on the right upper arm. 
An oscillometric pressure meter (Omron 705CP) or, if this failed, mercury sphygmomanometer were used. 
Three readings were taken 2 minutes apart, and the average of the three measurements was used..Blood samples 
were drawn after overnight fasting. Samples were analysed within 24 hours of sampling in the Oulu University 
Hospital laboratory using on-going internal/external quality control. Serum total cholesterol, high-density 
lipoprotein (HDL)-cholesterol, low-density lipoprotein (LDL)-cholesterol and triglyceride concentrations were 
analysed by Cobas Integra 700 automatic analyser (Roche Diagnostics, Basel, Switzerland). 
Genotyping:  
The NFBC1986 data were genotyped using Illumina iSelect Metabochip genotyping array. In quality control, 
samples were excluded due to call rate < 95%, low mean heterozygosity, duplicance (concordance with other 
DNA>0.99), IBS pairwise sharing >0.25, consent withdrawal, gender mismatch or being an MDS outlier. SNPs 
with call rate <95% or with MAF<5% and call rate <99% were excluded. After quality control, 4937 individuals 
and 133 991 SNPs were available for analysis. 
 
25. Orkney Complex Disease Study (ORCADES) 
Data collection: ORCADES is an on-going family-based, cross-sectional study in the isolated Scottish 
archipelago of Orkney. Genetic diversity in this population is decreased compared to Mainland Scotland, 
consistent with the high levels of endogamy historically.  Data for participants aged 18-100 years, from a 
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subgroup of ten islands, were used for this analysis. Fasting blood samples were collected and over 300 health-
related phenotypes and environmental exposures were measured in each individual. All participants gave 
informed consent and the study was approved by Research Ethics Committees in Orkney and Aberdeen. 
Measurement of clinical parameters: Weight and standing height were measured without shoes and in light 
clothing by a trained research nurse using Seca scales and stadiometer.  Body mass index was calculated as 
kg/m2. Two blood pressure measurements were taken with the participant seated for at least 5 minutes using an 
Omron automated digital sphygmomanometer (Omron, Tokyo, Japan). The average was used for analysis.  A 
large cuff was used if the mid-upper arm circumference was ≥32 cm. Fasting venous blood samples were 
analysed for total cholesterol and triglyceride levels by an auto-analyser using enzymatic methods. 
Genotyping: We genotyped 318,237 SNPs for each individual using the Illumina HumanHap300 beadchip. 
Alleles were called in BeadStudio using Illumina cluster files. Subjects were excluded if they fulfilled any of the 
following criteria: genotypic call rate <97%, mismatch between reported and genotypic sex, unexpectedly low 
genomic sharing with first degree relatives, excess autosomal heterozygosity, or outliers identified by IBS 
clustering analysis. We excluded SNPs on the basis of minor allele frequency (<0.01), HWE (P<10-5), call rate 
(<97%). Pregnant women were excluded from the study. MACH v1.0.15 was used to impute over 2 million 
SNPs from HapMap build 36.  
 
26. Osteoporotic Fractures in Men Study – Sweden (MrOS Sweden) 
Data collection: The MrOS study is a multicenter, prospective study including 3,014 elderly men in Sweden, 
Hong Kong (≈2,000), and the United States (≈6,000). The MrOS Sweden cohort consist of three sub-cohorts 
from three different Swedish cities (n=1,005 in Malmö, n=1,010 in Göteborg, and n=999 in Uppsala).26 Study 
subjects (men aged 69–80 years) were randomly identified using national population registers, contacted and 
asked to participate. To be eligible for the study, the subjects had to be able to walk without assistance, provide 
self-reported data, and sign an informed consent; there were no other exclusion criteria. (1) The study was 
approved by the ethics committees at the Universities of Gothenburg, Lund, and Uppsala. Informed consent was 
obtained from all study participants.  
Measurement of clinical parameters: Standard equipment was used to measure height and weight. Body mass 
index (BMI) was calculated as weight (kg)/height (m)2. Serum lipid analysis was performed on a Konelab 20 
autoanalyzer (Thermo Electron Corporation, Vantaa, Finland). Total cholesterol and triglyceride levels were 
determined in fasting serum by fully enzymatic techniques. With a standard mercury sphygmomanometer and a 
Doppler probe, we conducted duplicate measures of supine blood pressure in the right arm after subjects rested 
in a quiet room for at least 10 min. The study coordinator placed appropriately sized cuffs over the right upper 
arm, rapidly inflated them to 30 mm Hg above the audible systolic pressure, and then slowly deflated them over 
the artery. A hand-held Doppler (Huntleigh Mini Dopplex Model D900, Huntleigh Healthcare AB, Limhamn, 
Sweden) recorded the pressure in the artery as the first audible systolic pressure. After performing 2 
measurements, we used the mean value of systolic pressure taken in the right brachial artery. 
Genotyping: Genotyping of all SNPs was carried out on the entire MrOS Sweden cohort samples for which 
DNA was available (n = 2922, except rs4588 n=2445 ) by Kbioscience, who employ a novel form of 
competitive allele specific PCR (KASPar) and TaqmanTM system for genotyping. The call rates for the four 
SNPs were, rs10741657: 0.87, rs12785878: 0.97, rs6013897: 0.91 and rs4588: 0.81. The concordance rate was 
>97% and the HWE p values were > 10e-4. The SNP rs12794714 was imputed for 962 subjects using Illumina 
HumanOmni1_Quad_v1-0 B, with exclusion criteria: HWE-p < 10e-4, SNP call rate <0.98. 
 
27. Prevention of Renal and Vascular Endstage Disease (PREVEND) 
Data collection: The PREVEND study examines the risk factors for and the prevalence and consequences of 
microalbuminuria in otherwise healthy adults in the city of Groningen.27 A total of 85,421 people were invited 
to participate in the study and 40,856 responded. Of these, 8,592 were invited for further screening. From 1997 
on the death certificates of the PREVEND cohort of 8,592 subjects are available. Of these subjects the clinical 
non-fatal events are also registered using a database of hospital discharge diagnoses. In addition, these subjects 
are seen every 3-4 year on the out-patient PREVEND facility. 
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Measurement of clinical parameters: Body mass index (BMI) was calculated as the ratio between weight (kg) 
and the square of height (m) (weight/height2). Systolic and diastolic BP was calculated as the mean of the last 
two measurements of the two visits. Serum cholesterol and triglycerides were determined by Kodak Ektachem 
dry chemistry (Eastman Kodak, Rochester, NY, USA), an automated enzymatic method.  
Genotyping: DNA from 3,649 subjects was available for GWA analysis. GWA were carried out using 
commercial arrays, with imputation of missing genotypes to HapMap2. SNPs with low minor allele frequencies 
(<1%), call rates (<95%) or imputation quality (.info (IMPUTE) metrics <0.80) were excluded. 
 
28. Prospective Investigation of the Vasculature in Uppsala Seniors (PIVUS): 
Data collection: The PIVUS (http://www.medsci.uu.se/pivus/) has been described in detail previously.28 All 70-
year-old men and women living in Uppsala, Sweden, were eligible for the study, and 2025 randomly selected 
individuals were invited within 2 months of their 70th birthday from April 2001 to June 2004. Of these, 1016 
(50%) participated in the study. At the examination the participants underwent a blood pressure measurement 
and anthropometry, blood sampling after an overnight fast, routine medical history. In total, the present study 
included 1,013 individuals.  
Measurement of serum 25(OH)D: 25-hydroxyvitamin D2 and D3 in serum were measured as a standard 
procedure at the department of Clinical Chemistry at Uppsala University Hospital. The LIAISON® 25-
hydroxyvitamin D Assay (DiaSorin) uses chemiluminescent immunoassay technology. CV for inter-assay 
analyses is 18.4% at a 25-hydroxyvitamin D level of 39.5 nmol/L and 11.7% at 121.2 nmol/L. The intra-assay 
CV is 7.1% at 44.7 nmol/L and 3.6% at 120.0 nmol/L. 
Measurement of clinical parameters: Weight and standing height (n=1194) were measured without shoes and in 
light clothing by a trained nurse. Body mass index was calculated as weight (kg)/height (m)2. Blood pressure 
was measured in a supine position manually by a calibrated mercury sphygmomanometer (to the nearest mmHg) 
after at least 30 min of rest and the average of three recordings was used. Triglycerides and total cholesterol was 
measured with routine methods. Cholesterol and triglycerides concentrations were analyzed in serum and HDL 
was separated by precipitation with magnesium chloride/phototungstate by enzymatic techniques using IL Test 
Cholesterol Trinder’s Method and IL Enzymatic-colorimetric Method for use in a Monarch apparatus 
(Instrumentation Laboratories, Lexington, USA). 
Genotyping: The SNPs were genotyped as part of a larger panels of SNPs at the SNP technology platform at 
Uppsala University (http://www.genotyping.se/) on an Illumina BeadStation 500GX using Infinium iSelect and 
Golden Gate assays from Illumina Inc.29 Genotyping calls were performed with Illumina BeadStudio or GenCall 
software. Samples with low call rate (<90 %), excess heterozygosity or cryptic relatedness were excluded from 
analyses. SNPs with a call rate less than 90%, or that failed HWE (exact P-value<1x10-6) were excluded from 
the study. 
  
29. Second Northwick Park Heart Study (NPHSII) 
Data collection: NPHSII is a prospective study of unrelated healthy middle-aged Caucasian male subjects (age 
49-64 years) recruited between April 1989 and April 1994 from nine United Kingdom general practices.30 
Exclusion criteria were a history of MI, cerebrovascular disease, life-threatening malignancy or regular 
medication with aspirin or anticoagulants. Each man answered a questionnaire detailing lifestyle and medical 
history. At entry, systolic and diastolic (Korotkoff V) blood pressures (SBP and DBP respectively) were 
recorded twice with a random zero mercury sphygmomanometer after the subject had been seated for 5 minutes.  
Measurement of clinical parameters: At entry, systolic and diastolic (Korotkoff V) blood pressures (SBP and 
DBP respectively) were recorded twice with a random zero mercury sphygmomanometer after the subject had 
been seated for 5 minutes. The average of the two measurements was used for analysis. Serum cholesterol and 
triglyceride levels were determined by automated procedures (Sigma and Wako chemicals, respectively). The 
men did not fast for the study but had been instructed to avoid heavy meals. They were also requested to refrain 
from smoking and vigorous exercise from midnight before the examination. Height was recorded to the nearest 
0.1cm and weight to the nearest 0.1kg without shoes or outdoor clothing. Body mass index was calculated as 
weight/height^2. 
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Genotyping: DNA was extracted from whole blood using the salting out method. Genotyping was performed 
using TaqMan technology (Applied Biosciences (ABI), Warrington UK). The call rate for all the 4 SNPs was 
>98 % and all SNPs were in Hardy-Weinberg equilibrium.  
 
30. TRacking Adolescents' Individual Lives Survey (TRAILS)  
Data collection: TRAILS is a prospective cohort study of Dutch adolescents with bi- or triennial measurements 
from age 11 to at least age 25 and consists of a general population and a clinical cohort.31 In the population 
cohort, four assessment waves have been completed to date, which ran from March 2001 to July 2002 (T1), 
September 2003 to December 2004 (T2), September 2005 to August 2007 (T3), and October 2008 to September 
2010 (T4). Data for the present study were collected during the third assessment wave. At T1, 2230 
(pre)adolescents were enrolled in the study (response rate 76.0%, mean age 11.09, SD 0.55, 50.8% girls, of 
whom 81.4% (N = 1816, mean age 16.27, SD 0.73, 52.3% girls) participated at T3. 
Measurement of clinical parameters: Systolic and diastolic blood pressure were measured in duplicate with a 
Dinamap Critikon 1846SX (Critikon Inc, Tampa, FL), from which we calculated means. Hypertension was 
defined according to World Health Organization guidelines as systolic blood pressure ≥140 mmHg, or diastolic 
blood pressure ≥90 mmHg. None of the adolescents used antihypertensive medication. The number of 
hypertensive cases was too small to be analyzed reliably. We obtained a blood sample after >8 h of fasting for 
the measurement of triglycerides, total cholesterol, and HDL cholesterol (Roche Diagnostics). Non-fasting 
blood samples were excluded from the analyses. 
Genotyping: Genome-wide genotyping for 1491 individuals was done with the Illumina Cyto SNP12 v2 array 
and genotypes were called using Illumina's GenomeStudio. Samples were excluded when: call rate <95%, 
heterozygosity >4SD, duplicates, sex mismatch, or non-caucasian. SNPs were removed when: call rate < 95%, 
MAF<1%, HWE p-value<1e-04, chr X SNPs >1% heterozygous in men. The QC-ed data of 1352 individuals 
were imputed using IMPUTE2 and association analysis was performed with SNPTEST v2.2.0. 
 
31. Tromsø study 
Data collection: The Tromsø Study, conducted by the University of Tromsø in cooperation with the National 
Health Screening Service, is a longitudinal population-based multipurpose study focusing on lifestyle related 
diseases.32 The fourth survey was performed in 1994 and 27 158 subjects attended. A total of 9528 subjects 
were selected for participation in the present study and DNA successfully prepared and analyzed for at least one 
SNP in sera from 1994 in 9471 subjects. Among these, 4175 were included as control cohort to the rest of the 
subjects that were included because of diagnosed myocardial infarction, cancer, type 2 diabetes or death. 
Measurement of serum 25(OH)D: Serum levels of 25(OH)D3 were measured by an electrochemiluminescence 
immunoassay (ECLIA), using an automated clinical chemistry analyser (Modular E170, Roche Diagnostics®, 
Mannheim, Germany). The total analytical coefficient of variation (CV) for the 25(OH)D3 assay was 7.3 %.  
Measurement of clinical parameters: Height and weight were measured while the subjects wore light clothing 
and no shoes and Body mass index (BMI) calculated as kg/m2.  Blood pressure was measured with an automatic 
device (Dinamap Vital Signs Monitor 1846; Critikon Inc, Tampa, FL). The subjects were seated for 2 min. 
Three recordings were made at 2-min intervals, and the lowest of the two last value was used. Serum total 
cholesterol and triglycerides were analyzed by enzymatic colorimetric methods with commercial kits (CHOD-
PAP for cholesterol and GPO-PAP for triglycerides; Boehringer-Mannheim, Mannheim, FRG).  The reference 
range for cholesterol in our laboratory is 3.2 to 7.4 mmol/L for those aged 25 to 29 years, 3.7 to 8.3 mmol/L for 
those aged 30 to 39 years, and 4.1 to 8.7 mmol/L for those aged > 40 years. The reference range for triglycerides 
is 0.20 to 1.80 mmol/L.  
Genotyping: All genotyping was performed by KBioscience (http://www.kbioscience.co.uk) using KASP 
(KBioScience Allele-Specific Polymorphism) SNP genotyping system. KASP is a competitive allele-specific 
PCR incorporating a FRET (Fluorescence Resonance Energy Transfer) quencher cassette. In all genotyping 
plates no-template controls (NTCs) are included to demonstrate that any amplification in the sample wells is due 
solely to the presence of the sample DNA. Two separate manual quality control checks are performed, and the 
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data is also checked by specific software to determine that there are no incorrect call assignments, no samples 
too close or too far from the origin, no NTCs amplified, or any incorrect calls. The call rate for all the 4 SNPs 
was >98 % and the Hardy-Weinberg equilibrium P value was > 0.01.  
 
32. Twins UK 
Data collection: The Twins registry in St. Thomas' Hospital, King's College London recruited a total sample of 
11,000 identical and non-identical, mostly female Caucasian, twins from across the UK through national media 
campaigns.33 Their age ranges between 16 and 85 years. Over 7,000 twins have attended detailed clinical 
examinations with a wide range of phenotypes over last 18 years. All participants were recruited without 
presence or interest in any particular disease or trait. We used 1,930 individuals for the present study.  
Measurement of serum 25(OH)D: Total 25-hydroxy vitamin D levels were measured by radioimmunoassay 
using Diasorin RIA kit (Diasorin, Minnesota, USA). This assay has a detection limit of 4 nmol/L and CV of 
9.1% at 22 nmol/L. 
Measurement of clinical parameters: Weight and standing height were measured without shoes and in light 
clothing by a trained nurse. Body mass index was calculated as weight (kg)/height (m)2. Three blood pressure 
measurements were taken with the participant seated for at least 5 minutes. Hypertension was defined according 
to World Health Organization guidelines as systolic blood pressure ≥140 mmHg, or diastolic blood pressure ≥90 
mmHg, or current antihypertensive medication. Non-fasting venous blood samples were analysed for total 
cholesterol and triglyceride levels by an auto-analyser (Olympus AU640, Japan) using enzymatic methods.   
Genotyping: Genotyping in the TwinsUK study was performed using Illumina 610K SNP. Analyses were 
restricted to SNPs with call rate of genotype ≥ 98% with average heterozygosity within 3 SD of mean (< 
0.3042438 and > 0.3267991). MAF was set as >1% and HWE P > 10-4. IMPUTE software was used for 
imputation. 
 
33. Uppsala Longitudinal Study of Adult Men (ULSAM) 
Data collection: The ULSAM was initiated in 1970 when all men born during the years 1920-24 and living in 
Uppsala, Sweden were invited at age 50 to participate in a health survey focusing on identifying cardiovascular 
risk factors (http://www.pubcare.uu.se/ULSAM).34 The present analyses are based on measurements made at the 
third examination cycle of the ULSAM cohort, when participants were approximately 71 years old (1991-95, 
n=1221). Of these, 1,194 participants had measurements of plasma 25(OH)D and were included in this study. 
Measurement of serum 25(OH)D: Total plasma 25(OH)D, including 25-hydroxyvitamin D3 and D2, was 
determined with high-pressure liquid chromatography (HPLC) atmospheric pressure chemical ionization (APCI) 
mass spectrometry (MS) at Vitas, Oslo, Norway (www.vitas.no). HPLC was performed with a Hewlett Packard 
1100 liquid chromatography (Agilent Technologies, Palo Alto CA, USA) interfaced by APCI to a Hewlett 
Packard mass spectrometer operated in single-ion monitoring mode (SIM). Recovery is 95%; the method is 
linear from 5-400 nmol/L and the limit of detection is 1-4 nmol/L. The Coefficients of Variation (CV) for inter-
assay analyses are 7.6% at 25-hydroxyvitamin D concentrations of 47.8 nmol/L and 6.9% at 83.0 nmol/L. The 
intra-assay CV was 5.1% at 47.8 nmol/L and 6.1% at 83.0 nmol/L. The assay is accredited by the Vitamin D 
External Quality Assessment Scheme (DEQAS).  
Measurement of clinical parameters: Weight and standing height (n= 1,194) were measured without shoes and 
in light clothing by a trained nurse. Body mass index was calculated as weight (kg)/height (m)2. After the 
subject had rested for 10 minutes, blood pressure was measured with the subject in supine position. Systolic and 
diastolic blood pressures, defined as Korotkoff phases I and V, respectively, were recorded twice and to the 
nearest even mmHg. The mean of the two measurements were used. We measured fasting concentrations of 
serum triglycerides and total cholesterol by using IL Test Cholesterol Trinders’ Method and IL Test Enzymatic-
Colorimetric Method in a Monarch apparatus (Instrumentation Laboratories, Lexington, USA). 
Genotyping: The SNPs were genotyped as part of a larger panels of SNPs at the SNP technology platform at 
Uppsala University (http://www.genotyping.se/) on an Illumina BeadStation 500GX using Infinium iSelect and 
Golden Gate assays from Illumina Inc.. Genotyping calls were performed with Illumina BeadStudio or GenCall 
software. Samples with low call rate (<90 %), excess heterozygosity or cryptic relatedness were excluded from 
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analyses. SNPs with a call rate less than 90%, or that failed (exact P-value<1x10-6) were excluded from the 
study. 
   
34. Whitehall II (WII) Study  
Data collection: The Whitehall II study recruited 10,308 participants (70% men) between 1985 and 1989 from 
20 London-based Civil Service departments (Marmot et al., 1991; Marmot & Brunner, 2005). At phases 3 
(1991-3), 5 (1997-1999) and 7 (2002-2004) all participants known to be alive and in the country were invited to 
a clinic for anthropometric and biochemical screening. Of the baseline participants, 6156 participated in phase 7 
screening, at which DNA was collected.     
Measurement of clinical parameters: Weight was measured in underwear to the nearest 0.1 kg on Soehnle 
electronic scales. We measured height in bare feet to the nearest 1 mm by using a stadiometer with the 
participant standing erect with head in the Frankfort plane. We calculated body mass index as weight 
(kilograms)/height (metres) squared. We measured waist circumference, taken as the smallest circumference at 
or below the costal margin, with participants unclothed in the standing position by using a fibreglass tape 
measure at 600 g tension. We measured systolic blood pressure and diastolic blood pressure twice in the sitting 
position after five minutes’ rest with the Hawksley random zero sphygmomanometer. We took the average of 
the two readings to be the measured blood pressure. We took venous blood in the fasting state or at least five 
hours after a light, fat free breakfast, before a two hour 75 g oral glucose tolerance test was done. Serum for 
lipid analyses was refrigerated at −4°C and assayed within 72 hours. We used a Cobas Fara centrifugal analyser 
(Roche Diagnostics System, Nutley, NJ) to measure cholesterol and triglyceride concentrations.  
Genotyping: We extracted DNA from blood samples by using magnetic bead technology (Medical Solutions, 
Nottingham).  Genotyping was performed using the Illumina 50K IBC CVD chip or KASPar methodology. The 
call rates and the concordance rates of the four SNPs were >98%. The HWE p values were P>0.07.   
 
35. Young Finns Study:  
Data collection: The first cross-sectional survey was conducted in 1980 all around Finland.35 Total sample size 
was 4,320 boys and girls in 6 age cohorts (aged 3, 6, 9, 12, 15 and 18). These individuals were randomly chosen 
from the national register. A total of 3,596 individuals (83.2% of those invited) participated the study in 1980. 
After that, several follow-up studies of this cohort have been conducted. The latest follow-up was performed in 
2007, when the study subjects had reached the age of 30 to 45 years. In the latest follow-up in 2007 a total of 
2,204 subjects were examined.36 For the present study, we included 2,442 individuals with genotype, BMI and 
vitamin D measurements.  
Measurement of serum 25(OH)D: Serum 25(OH)D concentrations were determined using radioimmunoassay 
(DiaSorin, Stillwater, Minnesota). The detection limit was 3.8 nmol/l, sensitivity = 1 nmol/l, measurement range 
= 12.5 - 250 nmol/l, inter-assay CV 8.0% (n = 137) and intra-assay CV 1.8 – 11.0% (n = 5) at the mean level of 
43.8 nmol/l).  
Measurement of BMI: Weight and standing height (n=2170) were measured without shoes and in light clothing 
by a trained nurse. Body mass index was calculated as weight (kg)/height (m)2. Blood pressure was measured 
with a standard mercury sphygmomanometer in 1980 and 1983. In 1980, among 3-year-olds an ultrasound 
device was used. In 1986, 2001, and 2007, a random zero sphygmomanometer was used. The average of three 
measurements was always used in statistical analyses. Venous blood samples were drawn after an overnight fast. 
Standard methods were used for serum total cholesterol, triglycerides, and HDL-cholesterol. LDL-cholesterol 
concentration was calculated using Friedewald equation. 
Genotyping: The genome-wide single nucleotide polymorphisms (SNP) genotyping of YF-study was done by a 
custom Illumina BeadChip containing 670,000 SNPs and copy-number variant (CNV) probes from 2,442 YF 
participants (1,123 males, 1,319 females). The custom 670K chip shares 562,643 SNPs in common with the 
Illumina Human610 BeadChip. Genotypes were called using Illumina’s clustering algorithm (Illuminus). A total 
of 2,556 samples were genotyped. After initial clustering, we removed 2 individuals for poor call rates 
(CR<0.90), and 54 samples failed subsequent quality control (QC) (i.e., duplicated samples, heterozygosity, low 
call rate, or custom SNP fingerprint genotype discrepancy). The following filters were applied to the remaining 
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data: MAF 0.01, GENO 0.05, MIND 0.05, and HWE 1 x 10-6. Three of 2,500 individuals were removed for low 
genotyping (MIND > 0.05), 11,766 markers were excluded based on HWE test (P ≤ 1 x 10-6), 7,746 SNPs 
failed missingness test (GENO > 0.05), 34,596 SNPs failed frequency test (MAF < 0.01) and one individual 
failed gender check. None were removed by subsequent heterozygosity check.  In that point, there were 546,770 
SNPs and 2,496 individuals which were utilized to generate an identity-by-descent (IBD) matrix file in PLINK. 
There were 51 pairs of individuals with pi-hat greater than 0.2 thus these individuals removed due to possible 
relatedness. One of the pair was removed using greater missingness as criteria. After final frequency and 
genotyping running, there was 546,677 SNPs available from a sample of 2442 Young Finns individuals. 
Genotype imputation was performed for the YF SNP data using MACH with the HapMap (phase II, release 22 
CEU, NCBI build 36, dbSNP 126) haplotypes as reference. 
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II. Additional information 
1. Genotyping:  
The studies that did not have genotyped data analysed imputed or proxy SNPs (r2=1) as available (with a call 
threshold of 0.9 for the SNPs imputed with Impute; for those imputed with MACH, a call threshold of 0.8 was 
used). The genetic data for most studies was obtained from GWA platforms, but for some studies (EAS, HCS, 
DOPS, NFBC 1986, NPHSII, ELSA, WHII, DPP and MRC NSHD), variants were genotyped de novo. 
2. Overlap between D-CarDia and consortia-based studies:  
 
To increase the statistical power of our study, we meta-analysed our results with the data from the International 
Consortium for Blood Pressure (ICBP)37 when examining systolic (SBP) or diastolic (DBP) blood pressure as 
the outcome. ICBP comprises 69,395 individuals of European ancestry from 29 studies,37 and it included the 
1958BC, FHS, NFBC1966, Twins UK, ORCADES, CROATIA-VIS and InCHIANTI, which were also part of 
the D-CarDia collaboration. These overlapping studies were therefore excluded when meta-analyzing D-CarDia 
studies with the ICBP summary data (total N=146,581 after excluding overlapping studies). At the time of the 
study, hypertension had not been formally examined as an outcome in the ICBP consortium, and related 
coefficients were not available. Therefore, we used summary data from Cohorts for Heart and Aging Research 
in Genomic Epidemiology (CHARGE)38 (N=29,136) and Global BPgen (N=34,433)39 consortia when 
examining hypertension as the outcome. Studies that overlapped with D-CarDia collaboration were again 
excluded in the meta-analyses (CHARGE: FHS; Global BPgen: 1958BC, NFBC1966, InCHIANTI and Twins 
UK; combining D-CarDia, CHARGE and Global BPgen, total N=142,255 after excluding overlapping studies).  
 
3. Analyses on adolescents:  
 
Two studies on adolescents (GINILISA and GOOD, N=1,776) were available for investigating associations with 
25(OH)D, and four studies (GINILISA, GOOD, NFBC86 and TRAILS, N=8,591) for evaluating genetic 
associations with SBP and DBP (Figure 1).  
Analyses on adolescents confirmed the associations between the synthesis and metabolism scores with 25(OH)D 
[synthesis score: beta per allele 3·83% (95%CI: 2·43%,5·22%), P=7·3x10-8; metabolism score: beta 6·99 
(95%CI: 2·84%,11·14%), P=0·001] (Supplementary table 4). However, there was no phenotypic association 
between 25(OH)D and SBP [beta per 10% change 0·001 mmHg (95%CI: -0·03,0·03), P=0·94] or DBP [beta 
0·01 mmHg (95%CI: -0·01,0·02), P=0·36]. Furthermore, there was no evidence for an association between 
synthesis or metabolism scores with SBP or DBP [synthesis score: SBP, beta 0·11 mmHg (95%CI: -0·14,0·35), 
P=0·39 and DBP, beta -0·02 mmHg (95%CI: -0·18,0·15), P=0·82; metabolism score: SBP, beta -0·16 mmHg 
(95%CI: -0·45,0·14), P=0·29 and DBP, beta 0·05 mmHg (95%CI: -0·15,0·24), P=0·65].  
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IV. Supplementary tables 
Supplementary table 1: Effect allele frequencies and genotyping information for the four vitamin D- 
related single nucleotide polymorphisms (SNPs)  
Study 
DHCR7 (rs12785878, 
effect allele=G) 
CYP2R1 (rs12794714, 
effect allele=A) 
GC (rs2282679, effect 
allele=G 
CYP24A1 (rs6013897, 
effect allele=A) 
Genotyping 
EAF, 
% 
Genotyping 
EAF, 
% 
Genotyping 
EAF, 
% 
Genotyping 
EAF, 
% 
1958BC Genotyped 22 Genotyped 43 Genotyped 30 Genotyped 20 
CROATIA-Korcula Genotyped 34 Imputed 44 Imputed 30 Genotyped 18 
CROATIA-Split Genotyped 33 Imputed 47 Imputed 27 Genotyped 20 
CROATIA-Vis Genotyped 31 Imputed 48 Imputed 28 Genotyped 17 
DOPS Genotyped 31 Genotyped 40 Genotyped 27 Genotyped 20 
DPP¥ Genotyped 25 n/a - Genotyped 28 Genotyped 21 
EAS Genotyped 19 Genotyped 40 Genotyped 29 Genotyped 20 
ELSA Genotyped 23 Genotyped 43 Genotyped 29 Genotyped 19 
ESTHER* Genotyped 26 Genotyped 46 n/a - n/a - 
FHS Genotyped 26 Genotyped 43 Genotyped 28 Genotyped 21 
GENMETS Imputed 38 Genotyped 41 Genotyped 19 Imputed 23 
GOOD Genotyped 33 Imputed 42 Genotyped 25 Genotyped 21 
HBCS Imputed 38 Imputed 39 Imputed 20 Imputed 23 
HCS Genotyped 26 Genotyped 44 Genotyped 30 Genotyped 20 
Health ABC Imputed 26 Imputed 45 Imputed 29 Imputed 21 
InChianti Genotyped 25 Genotyped 48 Genotyped 25 Genotyped 24 
LifeLines Imputed 25 Imputed 42 Imputed 27 Imputed 13 
LISAplus & GINIplus Genotyped 28 Imputed 43 Genotyped 27 Genotyped 20 
LURIC Imputed 24 Imputed 45 Genotyped 28 Imputed 21 
GOYA Genotyped 30 Genotyped 40 Genotyped 28 Genotyped 20 
MRC NSHD Genotyped 22 Genotyped 42 Genotyped 28 Genotyped 20 
MrOS Sweden Genotyped 32 Imputed 42 Genotyped 26 Genotyped 20 
NESDA Imputed 27 Imputed 44 Imputed 28 Imputed 19 
NFBC 1966 Imputed 39 Imputed 39 Imputed 20 Imputed 23 
NFBC 1986 Genotyped 40 Genotyped 39 Genotyped 19 Genotyped 22 
NPHSII Genotyped 22 Genotyped 42 Genotyped 29 Genotyped 19 
ORCADES Genotyped 31 Imputed 38 Imputed 26 Genotyped 22 
PIVUS Genotyped 35 Genotyped 40 Genotyped 26 Genotyped 21 
PREVEND* Imputed 25 Imputed 44 Imputed 27 n/a - 
TRAILS Imputed 28 Imputed 41 Genotyped 27 Imputed 14 
Tromsø Genotyped 39 Genotyped 41 Genotyped 25 Genotyped 23 
Twins UK Genotyped 23 Genotyped 42 Genotyped 30 Genotyped 20 
ULSAM Genotyped 33 Genotyped 39 Genotyped 26 Genotyped 22 
Whitehall II Genotyped 23 Genotyped 42 Genotyped 29 Genotyped 20 
Young Finns Genotyped 40 Genotyped 38 Genotyped 19 Genotyped 24 
Studies with SNP imputed (% of 
total) 
9 (25) - 15 (43) - 10 (29) - 8 (23) - 
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Max N with SNP imputed (% of 
total N) 
31,815 (29) - 38,599 (36) - 29,270 (27) - 28,166 (26) - 
 
DHCR7, 7-dehydrocholesterol reductase; CYP2R1, 25-hydroxylase; GC, Vitamin D binding protein; CYP24A1, 
25-hydroxyvitamin D 24-hydroxylase; EAF, effect allele frequency 
* ESTHER and PREVEND studies were not included in the metabolism allele score, as the SNPs required for 
creating the allele score were not available. 
¥ The DPP study was not included in the synthesis allele score, as the CYP2R1 SNP required for creating the 
allele score was not available. 
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 Supplementary table 2: Effect allele frequencies of the four vitamin D- related single nucleotide polymorphisms (SNPs), mean age, mean body mass index (BMI) 
and 25-hydroxyvitamin D levels, stratified by geographical region (31 D-CarDia studies in adults) 
Geographical 
Region 
Countries in 
region Studies in region 
Studies with 
25(OH)D 
DHCR7 
EAF: 
mean 
(sd) 
CYP2R1 
EAF: 
mean 
(sd) 
GC 
EAF: 
mean 
(sd) 
CYP24A1 
EAF: 
mean (sd) 
Average 
study age: 
mean (sd) 
Average 
study 
BMI: 
mean (sd) 
Average 
study 
SBP: 
mean (sd) 
Average 
study 
DBP: 
mean (sd) 
% hyper-
tensive in 
study: 
mean (sd) 
Average 
study ln-
25(OH)D: 
mean (sd) 
Great Britain GB 58BC, EAS, ELSA, HCS, 
NPHSII, MRC NSHD, 
ORKNEY, Twins UK, 
WHII 
58BC, HCS, 
Twins UK 
0.23 
(0.03) 
0.42 
(0.02) 
0.29 
(0.01) 
0.20 
(0.01) 
57.13 
(7.67) 
26.87 
(0.89) 
134.74 
(6.51) 
79.08 
(3.95) 
42.99 
(11.26) 
3.97 
(0.25) 
Central and 
South Europe 
Croatia, 
Italy, 
Germany, 
Netherlands 
ESTHER, InChianti, 
KORCULA, Lifelines, 
NESDA, LURIC, 
PREVEND, SPLIT, VIS 
ESTHER, 
InChianti, 
LURIC 
0.28 
(0.04) 
0.45 
(0.02) 
0.28 
(0.01) 
0.19 
(0.03) 
54.99 
(8.49) 
26.96 
(0.78) 
140.06 
(8.5) 
84.96 
(6.36) 
51.54 
(20.79) 
3.74 
(0.11) 
Finland Finland GENMETS, HBCS, 
NFBC66, Young Finns 
GENMETS, 
NFBC66, Young 
Finns 
0.39 
(0.01) 
0.39 
(0.01) 
0.20 
(0.01) 
0.23 
(0.00) 
45.18 
(13.60) 
25.89 
(1.30) 
132.49 
(12.88) 
82.23 
(7.18) 
37.43 
(26.04) 
3.99 
(0.18) 
Scandanavia Denmark, 
Norway, 
Sweden 
DOPS, GOYA, MrOS, 
PIVUS, TROMSO, ULSAM 
DOPS, MrOS, 
PIVUS, 
TROMSO, 
ULSAM 
0.33 
(0.03) 
0.40 
(0.01) 
0.26 
(0.01) 
0.21 
(0.01) 
61.98 
(12.2) 
26.85 
(1.85) 
147.06 
(8.70) 
85.34 
(4.25) 
59.78 
(12.13) 
4.08 
(0.10) 
North America USA DPP, FHS, Health ABC DPP, FHS, 
Health ABC 
0.26 
(0.01) 
0.44 
(0.01) 
0.28 
(0.01) 
0.21 
(0.00) 
57.74 
(15.01) 
29.29 
(4.18) 
129.4 
(9.12) 
76.75 
(2.89) 
39.51 
(21.84) 
3.54 
(0.40) 
 EAF, Effect allele frequency; SBP, systolic blood pressure; DBP, diastolic blood pressure; sd, standard deviation 
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Supplementary table 3: Mutually adjusted association of log transformed 25(OH)D with confounding variables 
Covariate 
 
Study 
 
Beta (SE) 
 
P-value 
 
Age(i) DOPS -0.023 (0.143) 0.875 
 
ESTHER 0.026 (0.012) 0.026 
 
HCS -0.098 (0.240) 0.683 
 
LURIC 0.044 (0.007) <0.0001 
 
MrOS 0.072 (0.144) 0.616 
 
PIVUS 0.082 (0.055) 0.135 
 
TROMSO 0.025 (0.007) 0.0002 
 
ULSAM 0.017 (0.015) 0.251 
Meta-analysis: I2 = 0 % 0.032 (0.004) <0.0001 
Age-squared(ii) DOPS 0.0003 (0.001) 0.832 
 
ESTHER -0.0002 (0.0001) 0.008 
 
HCS 0.001 (0.002) 0.688 
 
LURIC -0.0004 (0.0001) <0.0001 
 
MrOS -0.0004 (0.001) 0.646 
 
TROMSO -0.0002 (0.0001) <0.0001 
Meta-analysis: I2 = 18 % -0.0003 (0.00004) <0.0001 
Sex 1958BC -0.069 (0.011) <0.0001 
 
ESTHER -0.164 (0.009) <0.0001 
 
HCS -0.173 (0.028) <0.0001 
 
LURIC -0.175 (0.020) <0.0001 
 
NFBC66 -0.011 (0.008) 0.130 
 
PIVUS -0.080 (0.023) 0.0005 
 
TROMSO -0.065 (0.009) <0.0001 
Meta-analysis: I2 = 97 % -0.104 (0.027) <0.0001 
Season(iii) 1958BC -0.387 (0.011) <0.0001 
 
DOPS -0.410 (0.027) <0.0001 
 
ESTHER -0.221 (0.009) <0.0001 
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HCS -0.389 (0.026) <0.0001 
 
LURIC -0.417 (0.018) <0.0001 
 
MrOS -0.152 (0.019) <0.0001 
 
NFBC66 -0.079 (0.010) <0.0001 
 
PIVUS -0.153 (0.022) <0.0001 
 
TROMSO -0.099 (0.009) <0.0001 
 
ULSAM -0.118 (0.019) <0.0001 
Meta-analysis: I2 = 99 % -0.242 (0.042) <0.0001 
BMI 1958BC -0.014 (0.001) <0.0001 
 
DOPS -0.011 (0.003) 0.001 
 
ESTHER -0.007 (0.001) <0.0001 
 
HCS -0.004 (0.003) 0.158 
 
LURIC -0.008 (0.002) 0.0002 
 
MrOS -0.010 (0.003) 0.0002 
 
NFBC66 -0.005 (0.001) <0.0001 
 
PIVUS -0.013 (0.003) <0.0001 
 
TROMSO -0.009 (0.001) <0.0001 
 
ULSAM -0.004 (0.003) 0.152 
Meta-analysis: I2 = 81 % -0.009 (0.001) <0.0001 
Total Cholesterol 1958BC -0.016 (0.005) 0.003 
 
DOPS 0.010 (0.013) 0.474 
 
ESTHER 0.001 (0.0001) <0.0001 
 
HCS -0.007 (0.012) 0.575 
 
LURIC 0.001 (0.0002) 0.0001 
 
MrOS 0.034 (0.009) 0.0002 
 
NFBC66 0.018 (0.004) 0.0002 
 
PIVUS -0.057 (0.011) <0.0001 
 
TROMSO 0.013 (0.004) 0.001 
 
ULSAM 0.010 (0.009) 0.302 
Meta-analysis: I2 = 89 % 0.002 (0.001) 0.052 
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Triglycerides 1958BC -0.016 (0.004) <0.0001 
 
DOPS -0.051 (0.022) 0.023 
 
ESTHER -0.0003 (0.00005) <0.0001 
 
HCS -0.060 (0.018) 0.0006 
 
LURIC -0.0003 (0.0001) 0.0002 
 
MrOS -0.049 (0.013) 0.0002 
 
NFBC66 0.010 (0.006) 0.091 
 
PIVUS -0.082 (0.018) <0.0001 
 
TROMSO -0.039 (0.005) <0.0001 
 
ULSAM 0.018 (0.013) 0.163 
Meta-analysis: I2 = 93 % -0.001 (0.001) 0.03 
(i) Main effect in model with squared term (uncentered) 
(ii) Squared term for age was not included for PIVUS or ULSAM studies, since the age range in the analysis sample for these studies was very small (range 69-71 and 59-73 
years respectively) 
(iii) In main analyses, models were adjusted for month; for these analyses a binary variable for season [winter/spring vs. summer/autumn] was used in order to present a single 
effect estimate for each study    
Random effects meta-analyses were used in the presence of heterogeneity (i.e. for all models except age/age2) 
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Supplementary table 4: Association of 25(OH)D increasing alleles in CYP2R1, DHCR7 and Synthesis score with potential confounding factors as outcomes  
          CYP2R1       DHCR7 Synthesis Score 
Outcome Study Beta (SE) P-value Beta (SE) P-value Beta (SE) P-value 
 Age DOPS -0.026 (0.102) 0.799 0.086 (0.108) 0.429 0.018 (0.078) 0.817 
  EAS 0.100 (0.290) 0.732 0.097 (0.343) 0.778 0.131 (0.232) 0.572 
  ELSA 0.141 (0.194) 0.467 0.176 (0.225) 0.435 0.181 (0.154) 0.242 
  ESTHER 0.184 (0.104) 0.077 0.209 (0.119) 0.079 0.206 (0.081) 0.011 
  HBCS -0.076 (0.103) 0.463 -0.076 (0.104) 0.465 -0.074 (0.078) 0.338 
  HCS -0.042 (0.076) 0.584 0.104 (0.116) 0.370 0.001 (0.081) 0.994 
  LURIC -0.070 (0.277) 0.801 0.542 (0.324) 0.095 0.201 (0.226) 0.374 
  MrOS -0.117 (0.154) 0.447 0.022 (0.090) 0.807 0.074 (0.118) 0.531 
  NPHSII 0.089 (0.099) 0.367 0.073 (0.112) 0.511 0.074 (0.078) 0.345 
  PIVUS -0.005 (0.010) 0.619 -0.005 (0.010) 0.583 -0.005 (0.008) 0.484 
  TROMSO 0.182 (0.204) 0.373 -0.190 (0.203) 0.348 -0.027 (0.153) 0.861 
  ULSAM -0.009 (0.028) 0.735 -0.008 (0.028) 0.781 -0.004 (0.021) 0.848 
  WHII 0.041 (0.127) 0.748 0.070 (0.150) 0.641 0.031 (0.101) 0.756 
  Meta-analysis -0.004 (0.009) 0.671 -0.002 (0.009) 0.804 -0.002 (0.007) 0.751 
   I2 = 0 Phet = 0.843 I2 = 0 Phet = 0.577 I2 = 0 Phet = 0.459 
ln BMI 1958BC 0.003 (0.003) 0.315 -0.001 (0.004) 0.681 0.002 (0.002) 0.478 
  DOPS 0.013 (0.006) 0.021 -0.004 (0.006) 0.518 0.006 (0.004) 0.219 
  EAS -0.002 (0.007) 0.743 0.004 (0.009) 0.623 -0.000 (0.006) 0.951 
  ELSA -0.002 (0.003) 0.639 0.002 (0.004) 0.678 -0.001 (0.003) 0.839 
  ESTHER -0.005 (0.002) 0.044 -0.000 (0.003) 0.899 -0.002 (0.002) 0.319 
  HBCS -0.007 (0.006) 0.209 -0.002 (0.006) 0.696 -0.005 (0.004) 0.226 
  HCS 0.004 (0.004) 0.355 -0.004 (0.007) 0.585 -0.001 (0.005) 0.813 
  LURIC 0.003 (0.004) 0.415 -0.003 (0.004) 0.436 -0.001 (0.003) 0.695 
  MrOS -0.003 (0.006) 0.591 -0.003 (0.004) 0.427 -0.005 (0.005) 0.252 
  NFBC66 -0.003 (0.003) 0.312 -0.003 (0.003) 0.419 -0.003 (0.003) 0.186 
  NPHSII -0.001 (0.004) 0.824 0.011 (0.004) 0.009 0.005 (0.003) 0.1 
  PIVUS -0.004 (0.008) 0.64 0.010 (0.007) 0.15 0.003 (0.006) 0.651 
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  TROMSO 0.004 (0.002) 0.112 -0.000 (0.002) 0.962 0.001 (0.002) 0.446 
  ULSAM -0.013 (0.005) 0.022 -0.007 (0.006) 0.194 -0.009 (0.004) 0.026 
  WHII 0.006 (0.003) 0.076 0.007 (0.004) 0.06 0.007 (0.003) 0.012 
  Meta-analysis 0.000 (0.001) 0.975 0.000 (0.001) 0.855 -0.000 (0.001) 0.99 
   I2 = 47 Phet = 0.024 I2 = 20 Phet = 0.233 I2 = 38 Phet = 0.069 
Total  1958BC -0.004 (0.020) 0.841 0.022 (0.023) 0.336 0.007 (0.016) 0.676 
Cholesterol DOPS 0.028 (0.044) 0.526 0.029 (0.047) 0.533 0.038 (0.034) 0.262 
  EAS -0.029 (0.068) 0.669 0.122 (0.081) 0.131 0.047 (0.054) 0.384 
  ELSA 0.010 (0.024) 0.679 0.002 (0.028) 0.943 0.007 (0.019) 0.716 
  ESTHER 0.652 (0.825) 0.43 1.138 (0.944) 0.228 0.695 (0.639) 0.277 
  HBCS -0.030 (0.037) 0.42 -0.005 (0.038) 0.896 -0.018 (0.028) 0.53 
  HCS 0.034 (0.032) 0.294 0.055 (0.053) 0.296 0.064 (0.037) 0.086 
  LURIC -1.894 (1.142) 0.097 0.584 (1.326) 0.66 -1.098 (0.927) 0.236 
  MrOS 0.009 (0.050) 0.852 -0.018 (0.051) 0.718 -0.014 (0.038) 0.706 
  NFBC66 0.028 (0.021) 0.185 0.010 (0.021) 0.618 0.024 (0.015) 0.118 
  NPHSII 0.073 (0.029) 0.013 0.039 (0.033) 0.239 0.057 (0.023) 0.015 
  PIVUS -0.042 (0.048) 0.384 -0.009 (0.047) 0.85 -0.022 (0.036) 0.541 
  TROMSO 0.019 (0.020) 0.345 -0.031 (0.020) 0.111 -0.011 (0.015) 0.447 
  ULSAM -0.019 (0.043) 0.659 -0.019 (0.044) 0.67 -0.016 (0.032) 0.609 
  WHII 0.027 (0.022) 0.212 0.032 (0.026) 0.206 0.031 (0.017) 0.073 
  Meta-analysis 0.016 (0.008) 0.045 0.007 (0.009) 0.383 0.013 (0.006) 0.039 
   I2 = 0 Phet = 0.503 I2 = 0 Phet = 0.628 I2 = 18 Phet = 0.258 
ln  1958BC -0.005 (0.011) 0.617 -0.005 (0.013) 0.718 -0.004 (0.009) 0.658 
Triglycerides DOPS 0.009 (0.017) 0.59 -0.005 (0.019) 0.783 0.003 (0.013) 0.814 
  EAS -0.020 (0.023) 0.384 -0.002 (0.027) 0.949 -0.014 (0.019) 0.467 
  ELSA -0.011 (0.010) 0.284 -0.029 (0.012) 0.015 -0.019 (0.008) 0.019 
  ESTHER -0.011 (0.009) 0.219 0.007 (0.010) 0.526 -0.003 (0.007) 0.638 
  HBCS -0.025 (0.016) 0.131 -0.040 (0.016) 0.017 -0.035 (0.012) 0.004 
  HCS 0.020 (0.013) 0.111 0.016 (0.021) 0.465 0.013 (0.015) 0.376 
  LURIC -0.010 (0.013) 0.435 0.009 (0.015) 0.565 -0.005 (0.010) 0.638 
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  MrOS 0.003 (0.021) 0.879 -0.000 (0.021) 0.991 0.001 (0.016) 0.946 
  NFBC66 0.004 (0.011) 0.73 0.003 (0.010) 0.798 0.005 (0.008) 0.535 
  NPHSII 0.008 (0.015) 0.586 0.017 (0.017) 0.329 0.012 (0.012) 0.327 
  PIVUS 0.009 (0.021) 0.669 0.010 (0.020) 0.623 0.009 (0.016) 0.565 
  TROMSO -0.001 (0.008) 0.927 -0.013 (0.008) 0.107 -0.009 (0.006) 0.162 
  ULSAM -0.020 (0.020) 0.325 -0.023 (0.021) 0.274 -0.019 (0.015) 0.207 
  WHII -0.000 (0.011) 0.968 0.015 (0.013) 0.242 0.006 (0.009) 0.459 
  Meta-analysis -0.003 (0.003) 0.351 -0.004 (0.004) 0.259 -0.004 (0.003) 0.088 
   I2 = 0 Phet = 0.753 I2 = 24 Phet = 0.193 I2 = 25 Phet = 0.177 
Sex 1958BC -0.063 (0.036) 0.08 0.078 (0.041) 0.058 -0.006 (0.028) 0.844 
  EAS 0.081 (0.103) 0.434 -0.023 (0.122) 0.852 0.047 (0.082) 0.565 
  ELSA 0.004 (0.040) 0.912 0.003 (0.047) 0.946 -0.001 (0.032) 0.97 
  ESTHER 0.018 (0.032) 0.566 -0.024 (0.036) 0.513 -0.001 (0.025) 0.958 
  HBCS 0.043 (0.071) 0.549 0.146 (0.072) 0.042 0.107 (0.054) 0.046 
  HCS 0.045 (0.054) 0.398 0.170 (0.089) 0.056 0.035 (0.062) 0.574 
  LURIC -0.078 (0.057) 0.168 0.004 (0.066) 0.954   
  NFBC66 -0.028 (0.043) 0.521 0.018 (0.043) 0.667 -0.008 (0.032) 0.792 
  PIVUS 0.096 (0.096) 0.319 -0.035 (0.093) 0.704 0.039 (0.072) 0.587 
  TROMSO -0.026 (0.030) 0.394 -0.009 (0.030) 0.772 -0.012 (0.022) 0.599 
  WHII -0.047 (0.050) 0.346 0.017 (0.059) 0.771 -0.034 (0.039) 0.39 
  Meta-analysis -0.013 (0.013) 0.329 0.018 (0.015) 0.233 -0.003 (0.011) 0.808 
   I2 = 0 Phet = 0.527 I2 = 8 Phet = 0.365 I2 = 0 Phet = 0.739 
Season** 1958BC -0.028 (0.038) 0.461 -0.065 (0.042) 0.126 -0.047 (0.030) 0.113 
  DOPS -0.091 (0.072) 0.206 0.058 (0.077) 0.45 -0.035 (0.056) 0.533 
  ESTHER 0.002 (0.031) 0.958 -0.018 (0.036) 0.616 -0.009 (0.024) 0.702 
  HCS 0.015 (0.053) 0.775 -0.109 (0.089) 0.224 -0.046 (0.062) 0.463 
  LURIC -0.051 (0.052) 0.331 0.062 (0.061) 0.312 -0.014 (0.043) 0.734 
  MrOS -0.040 (0.097) 0.677 0.124 (0.101) 0.216 0.057 (0.074) 0.437 
  NFBC66 -0.011 (0.047) 0.815 0.067 (0.046) 0.149 0.030 (0.034) 0.382 
  PIVUS 0.035 (0.097) 0.715 0.144 (0.094) 0.125 0.122 (0.073) 0.095 
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  TROMSO 0.050 (0.043) 0.251 0.089 (0.043) 0.039 0.078 (0.033) 0.016 
  ULSAM -0.058 (0.087) 0.508 0.064 (0.089) 0.468 -0.007 (0.065) 0.91 
  Meta-analysis -0.009 (0.016) 0.575 0.031 (0.024) 0.197 0.007 (0.017) 0.672 
   I2 = 0 Phet = 0.836 I2 = 38 Phet = 0.105 I2 = 33 Phet = 0.142 
Current  1958BC 0.042 (0.042) 0.322 -0.027 (0.048) 0.57 0.020 (0.033) 0.557 
 smoking EAS 0.166 (0.126) 0.188 -0.199 (0.144) 0.168 0.012 (0.099) 0.905 
  ELSA 0.066 (0.059) 0.261 -0.056 (0.067) 0.404 0.012 (0.047) 0.804 
  ESTHER -0.086 (0.042) 0.042 -0.000 (0.049) 0.998 -0.054 (0.033) 0.098 
  HBCS -0.003 (0.081) 0.97 0.009 (0.082) 0.909 0.024 (0.061) 0.692 
  HCS -0.036 (0.081) 0.656 -0.030 (0.127) 0.813 0.000 (0.089) 0.998 
  LURIC 0.072 (0.062) 0.249 -0.036 (0.072) 0.614 0.029 (0.051) 0.571 
  MrOS 0.183 (0.180) 0.312 -0.019 (0.184) 0.919 0.096 (0.136) 0.478 
  NFBC66 -0.096 (0.046) 0.036 -0.022 (0.045) 0.626 -0.070 (0.033) 0.036 
  NPHSII 0.084 (0.064) 0.187 0.069 (0.073) 0.343 0.095 (0.051) 0.061 
  PIVUS 0.511 (0.166) 0.002 -0.143 (0.147) 0.332 0.204 (0.117) 0.082 
  TROMSO -0.011 (0.032) 0.719 0.006 (0.031) 0.86 -0.003 (0.024) 0.893 
  ULSAM 0.054 (0.108) 0.617 -0.095 (0.109) 0.384 -0.021 (0.081) 0.796 
  WHII -0.035 (0.077) 0.649 0.248 (0.098) 0.011 0.073 (0.062) 0.237 
  Meta-analysis 0.018 (0.025) 0.473 -0.007 (0.017) 0.701 -0.001 (0.012) 0.96 
   I2 = 52 Phet = 0.013 I2 = 0 Phet = 0.491 I2 = 21 Phet = 0.220 
Phet: heterogeneity p-value  
Estimates are from linear regression for continuous outcomes (age, BMI, total Cholesterol, triglycerides) and logistic regression for binary outcomes (sex, season 
[winter/spring vs. summer/autumn] and current smoking). Random effects models were used for all meta-analyses indicating high levels of heterogeneity (judged by I-
squared > 30%), otherwise fixed effects models were used. 
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Supplementary table 5: Association of the vitamin D-related SNPs and allele scores with 25-hydroxyvitamin D concentrations (D-CarDia, N up to 49,346 adults and 
1,776 adolescents).   
 
Instrument Studies included Coefficient (95% CI) MA  P-value Heterogeneity P-value I-squared, % MA model 
DHCR7 Adults 3.29 (2.41, 4.17) <0.0001 0.0006 60.6 Random 
  Adolescents 4.06 (2.08, 6.05) <0.0001 0.89 0 Fixed 
CYP2R1 Adults 2.58 (2.12, 3.05) <0.0001 0.21 21.2 Fixed 
  Adolescents 3.38 (1.52, 5.23) 0.0004 0.26 22.1 Fixed 
Synthesis score Adults 2.83 (2.48, 3.19) <0.0001 0.48 0 Fixed 
  Adolescents 3.83 (2.43, 5.22) <0.0001 0.31 2.2 Fixed 
GC Adults 8.54 (7.43, 9.65) <0.0001 <0.0001 67.8 Random 
  Adolescents 9.51 (2.26, 16.75) 0.01 0.0003 92.2 Random 
CYP24A1 Adults 2.1 (1.51, 2.68) <0.0001 0.86 0 Fixed 
  Adolescents 3.77 (1.53, 6.01) 0.0001 0.97 0 Fixed 
Metabolism score Adults 5.38 (4.67, 6.08) <0.0001 0.003 57.0 Random 
   Adolescents 6.99 (2.84, 11.14) 0.0001 0.01 86.5 Random 
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Supplementary table 6: Association between DHCR7, CYP2R1 and the synthesis score with blood pressure and hypertension, with and without adjustment for 
serum lipids. Subsample of D-CarDia cohorts with full information on DHCR7, CYP2R1, blood pressures and lipids (29 studies, n=81,905).*  
 
 
Adjustment* Coefficient SE I2 % MA model 
Systolic BP DHCR7 Basic -0.075 0.140 44.9 Random 
  
+ Lipids -0.083 0.136 41.9 Random 
 
CYP2R1 Basic -0.071 0.084 0 Fixed 
  
+ Lipids -0.054 0.084 0 Fixed 
 
Synthesis score Basic -0.114 0.079 20.3 Fixed 
  
+ Lipids -0.108 0.064 22.4 Fixed 
Diastolic BP DHCR7 Basic -0.103 0.085 44.7 Random 
  
+ Lipids -0.113 0.084 43.5 Random 
 
CYP2R1 Basic -0.089 0.051 3.4 Fixed 
  
+ Lipids -0.075 0.051 5.3 Fixed 
 
Synthesis score Basic -0.103 0.053 30.6 Random 
  
+ Lipids -0.102 0.055 35.4 Random 
Hypertension DHCR7 Basic -0.008 0.019 51.2 Random 
  
+ Lipids -0.014 0.018 41.6 Random 
 
CYP2R1 Basic -0.014 0.011 0 Fixed 
  
+ Lipids -0.010 0.011 0 Fixed 
 
Synthesis score Basic -0.016 0.009 1.5 Fixed 
  
+ Lipids -0.013 0.009 0 Fixed 
*Two studies excluded, which did not have information on lipids.
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Supplementary table 7: Associations between DHCR7 and CYP2R1 with 25(OH)D, SBP, DBP and Hypertension for genotyped vs. imputed SNPs in 31 adult D-
CarDia cohorts (N up to 99,582).  
    Genotyping # studies total N Coefficient SE I2 % MA model 
25(OH)D DHCR7 Genotyped 13 38,829 0.034 0.005 59.6 Random 
  Imputed  4 9,650 0.029 0.009 54.5 Random 
         
 CYP2R1 Genotyped 12 35,211 0.025 0.003 23.0 Fixed 
  Imputed  4 9,784 0.029 0.004 24.0 Fixed 
Systolic BP DHCR7 Genotyped 23 63,693 -0.154 0.177 47.7 Random 
  Imputed  8 30,122 0.073 0.184 19.4 Random 
         
 CYP2R1 Genotyped 18 59,455 -0.058 0.107 0.0 Fixed 
  Imputed  12 33,120 -0.046 0.131 0.0 Fixed 
Diastolic BP DHCR7 Genotyped 23 63,689 -0.170 0.095 35.8 Random 
  Imputed  8 30,117 0.062 0.156 51.6 Random 
         
 CYP2R1 Genotyped 18 59,451 -0.088 0.065 11.8 Fixed 
  Imputed  12 33,115 -0.077 0.081 0.0 Fixed 
Hypertension DHCR7 Genotyped 23 65,724 -0.017 0.022 47.9 Random 
  Imputed  8 30,118 0.012 0.040 57.1 Random 
         
 CYP2R1 Genotyped 18 59,599 -0.011 0.013 0.0 Fixed 
   Imputed  12 33,150 -0.019 0.020 0.0 Fixed 
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Supplementary table 8: Comparison of adjustments to blood pressure values for individuals taking medication, with 15 mmHg added to SBP and 10mmHg to DBP 
being compared to 10mmHg to SBP [SBP (ii) in table] and 5 mmHg to DBP [DBP (ii) in table]. Subsample of D-CarDia cohorts with individual level data and full 
information on DHCR7, CYP2R1, blood pressures and 25(OH)D (10 studies, n up to 34,609).  
Exposure Outcome Coefficient SE I2 % MA model 
25(OH)D SBP -0.160 0.091 64.6 Random 
 
SBP (ii) -0.149 0.092 67.0 Random 
 
DBP -0.004 0.068 78.5 Random 
 
DBP (ii) 0.006 0.069 80.7 Random 
CYP2R1 SBP -0.187 0.130 11.7 Fixed 
 
SBP (ii) -0.166 0.127 13.9 Fixed 
 
DBP -0.107 0.081 20.8 Fixed 
 
DBP (ii) -0.085 0.079 34.1 Fixed 
DHCR7 SBP -0.106 0.279 65.1 Random 
 
SBP (ii) -0.114 0.272 65.1 Random 
 
DBP -0.137 0.172 66.4 Random 
 
DBP (ii) -0.148 0.160 64.2 Random 
Synthesis score SBP -0.238 0.100 0 Fixed 
 SBP (ii) -0.230 0.099 3.4 Fixed 
 
DBP -0.143 0.064 0 Fixed 
 
DBP (ii) -0.132 0.062 6.0 Fixed 
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Supplementary table 9: Comparing genetically indexed association obtained by the Instrumental Variable (IV) ratio method [2-staged IV, as used in main analyses] 
and meta-analyses of study specific IV ratios [MA of IV ratios] in the Subsample of D-CarDia cohorts with individual level data and full information on DHCR7, 
CYP2R1, blood pressures and 25(OH)D (10 studies, n up to 34,609). 
Outcome Method Coefficient* SE I2 % MA model 
Systolic BP 2-staged IV  -0.085 0.039 28.9 [1
st stage MA] 
0 [2nd stage MA] Fixed [both stages] 
 MA of IV ratios -0.076 0.035 0 Fixed 
Diastolic BP 2-staged IV  -0.057 0.025 28.9 [1
st stage MA] 
0 [2nd stage MA] Fixed [both stages] 
  MA of IV ratios -0.044 0.022 0 Fixed 
Hypertension 2-staged IV  -0.005 0.005 28.9 [1
st stage MA] 
0 [2nd stage MA] Fixed [both stages] 
  MA of IV ratios -0.005 0.005 0 Fixed 
IV, Instrumental variable; MA, Meta-analysis 
1st stage MA: meta-analysis of association of the instrument with the outcome 
2nd stage MA: meta-analysis of association of the instrument with 25(OH)D 
 
* The difference in BP mmHg or difference in log odds of hypertension, per % increase in 25(OH)D. 
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Supplementary table 10: Summary of coefficients for the instrumental variable (IV) ratio analyses in adult cohorts, using the Synthesis score and its components as 
instrumental variables. Includes summary data from ICBP/CHARGE/Global BPgen consortiums (N up to 146,581, overlapping studies excluded). 
  
Outcome 
Synthesis score 
& its 
components 
SNP with 25(OH)D, per allele SNP with outcome, per allele IV estimate for causal effect, per 10% increase in 25(OH)D  
Coefficient, % (95% CI) Coefficient % (95% CI) Coefficient (95% CI) 
Systolic blood pressure DHCR7 3.29 (2.41, 4.17) -0.11 (-0.39, 0.18) -0.32 (-1.18, 0.54) 
(mmHg) CYP2R1 2.58 (2.12, 3.05) -0.08 (-0.22, 0.05) -0.32 (-0.86, 0.21) 
  Synthesis score 2.83 (2.48, 3.18) -0.10 (-0.21, -0.0001) -0.37 (-0.73, 0.003) 
Diastolic blood pressure DHCR7 3.29 (2.41, 4.17) -0.09 (-0.25, 0.08) -0.26 (-0.78, 0.26) 
(mmHg) CYP2R1 2.58 (2.12, 3.05) -0.09 (-0.18, -0.01) -0.35 (-0.68, -0.03) 
  Synthesis score 2.83 (2.48, 3.18) -0.08 (-0.15, -0.02) -0.29 (-0.52, -0.07) 
Hypertension DHCR7 3.29 (2.41, 4.17) 0.98 (0.95, 1.02) 0.95 (0.85, 1.07) 
 CYP2R1 2.58 (2.12, 3.05) 0.98 (0.96, 1.00) 0.92 (0.85, 0.99) 
  Synthesis score 2.83 (2.48, 3.18) 0.98 (0.96, 0.99) 0.92 (0.87, 0.97) 
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V. Supplementary figures 
Supplementary figure 1: Flow chart showing the statistical analyses involved at each stage of the meta-analyses 
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Supplementary figure 2: Association of the 25-hydroxyvitamin D concentrations with systolic (A) and diastolic (B) blood pressures and hypertension (C) (D-
CarDia, up to N=49,363).   Coefficients corresponding to change in blood pressure (mmHg) or odds of hypertension per 10% increment in 25(OH)D 
                 A                                                                   B                                                                        C 
NOTE: Weights are from random effects analysis
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Supplementary figure 3A: Association of the four vitamin D SNPs with systolic blood pressure (meta-
analysis of the results from D-CarDia and ICBP consortium, up to 146,581 adults (overlapping studies 
excluded) and 8,591 adolescents 
 
NOTE: Weights are from random effects analysis
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Supplementary figure 3B: Association of the four vitamin D SNPs with diastolic blood pressure (meta-
analysis of the results from D-CarDia and ICBP consortium, up to 146,581 adults (overlapping studies 
removed) and 8,591 adolescents  
NOTE: Weights are from random effects analysis
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Supplementary figure 3C: Association of the four vitamin D SNPs with hypertension (meta-analysis of the 
results from D-CarDia, CHARGE and Global BPgen consortiums, up to N=142,255, overlapping studies 
excluded)   
 
NOTE: Weights are from random effects analysis
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Supplementary figure 4: Association of the metabolism allele score with systolic (A) and diastolic (B) blood pressures and hypertension (C) (D-CarDia and 
ICBP/CHARGE/Global BPgen consortiums, up to 146,581 adults (overlapping studies removed) and 8,591 adolescents   
A                                                                     B                                                                      C 
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SNP genotyping for the CROATIA-Korcula cohort was performed in Helmholtz Zentrum München, Neuherberg, Germany. 
3. CROATIA-Split: The CROATIA-Split study is funded by grants from the Medical Research Council (UK), European Commission Framework 6 project EUROSPAN 
(Contract No. LSHG-CT-2006-018947) and Republic of Croatia Ministry of Science, Education and Sports research grants to I.R.   
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(108-1080315-0302). We would like to acknowledge the staff of several institutions in Croatia that supported the field work, including but not limited to The University of 
Split and Zagreb Medical Schools and the Croatian Institute for Public Health. The SNP genotyping for the CROATIA-Split cohort was performed by AROS Applied 
Biotechnology, Aarhus, Denmark. 
4. CROATIA-Vis: The CROATIA-Vis study was funded by grants from the Medical Research Council (UK) and Republic of Croatia Ministry of Science, Education and 
Sports research grants to I.R. (108-1080315-0302). We would like to acknowledge the staff of several institutions in Croatia that supported the field work, including but not 
limited to The University of Split and Zagreb Medical Schools, the Institute for Anthropological Research in Zagreb and Croatian Institute for Public Health. The SNP 
genotyping for the CROATIA-Vis cohort was performed in the core genotyping laboratory of the Wellcome Trust Clinical Research Facility at the Western General Hospital, 
Edinburgh, Scotland. 
5. Danish Osteoporosis Prevention Study (DOPS): Genotyping was funded by the British Heart Foundation (grant PG/09/023). The study was supported by grants from the 
Karen Elise Jensen’s Foundation, Aarhus University, and the Danish Medical Research Council. A list of centres and investigators are available at www.ClinicalTrials.gov 
(NCT00252408). 
6. Diabetes Prevention Program (DPP): The NIDDK of the National Institutes of Health provided funding to the clinical centers and the Coordinating Center for the design 
and conduct of the study; collection, management, analysis, and interpretation of the data.  The Southwestern American Indian Centers were supported directly by the 
NIDDK and the Indian Health Service. The General Clinical Research Center Program, National Center for Research Resources supported data collection at many of the 
clinical centers. Funding for data collection and participant support was also provided by the Office of Research on Minority Health, the National Institute of Child Health 
and Human Development, the National Institute on Aging, the Centers for Disease Control and Prevention, Office of Research on Women's Health, the Department of 
Veterans Affairs, and the American Diabetes Association. The opinions expressed are those of the investigators and do not necessarily reflect the views of the Indian Health 
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Service or other funding agencies.  A complete list of centers, investigators, and staff can be found in the previously published study (The Diabetes Prevention Program: 
baseline characteristics of the randomized cohort. The Diabetes Prevention Program Research Group. Diabetes Care. 2000; 23(11): 1619-29).  
The investigators gratefully acknowledge the commitment and dedication of all participants in the DPP, without whom this work would not have been possible. This work 
was funded by R01 DK072041 to JCF and KAJ. JCF has received consulting honoraria from Lilly.  
7. Edinburgh Artery Study (EAS): We thank all participants and staff involved in the EAS.   The study was funded by the British Heart Foundation. 
8. English Longitudinal Study of Ageing (ELSA): Genotyping was funded by the British Heart Foundation (grant PG/09/023). Samples from the English Longitudinal 
Study of Ageing (ELSA) DNA Repository (EDNAR), received support under a grant (AG1764406S1) awarded by the National Institute on Ageing (NIA). ELSA was 
developed by a team of researchers based at the National Centre for Social Research, University College London and the Institute of Fiscal Studies. The data were collected 
by the National Centre for Social Research. 
9. ESTHER: Vitamin D measurements were performed in the context of the German Cancer Aid project number 108250 and 108426 and the CHANCES project funded in 
the FP7 framework programme of DG-RESEARCH in the European Commission (Grant no. 242244). The ESTHER study was funded by the Baden-Württemberg state 
Ministry of Science, Research and Arts (Stuttgart, Germany), the Federal Ministry of Education and Research (Berlin, Germany) and the Federal Ministry of Family Affairs, 
Senior Citizens, Women and Youth (Berlin, Germany). 
10. Framingham Heart Study (FHS): The Framingham Heart Study of the National Heart, Lung and Blood Institute of the National Institutes of Health and Boston 
University School of Medicine is supported by the NIH/NHLBI contract N01-HC-25195. The analyses reflect intellectual input and resource development from the 
Framingham Heart Study investigators participating in the SNP Health Association Resource (SHARe) project. This work was partially supported by a contract with 
Affymetrix, Inc for genotyping services (Contract No. N02-HL-6-4278). A portion of this research utilized the Linux Cluster for Genetic Analysis (LinGA-II) funded by the 
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Robert Dawson Evans Endowment of the Department of Medicine at Boston University School of Medicine and Boston Medical Center. Funding was also received from the 
American Heart Association. 
11. Gothenburg Osteoporosis and Obesity Determinants (GOOD) Study: This study was supported by the Swedish Research Council, the Lundberg Foundation, and 
ALF/LUA grants from the Sahlgrenska, University Hospital. 
12. Health2000 GenMets (GENMETS) Study: V.S. was supported by grants #139635 and #129494 from the Academy of Finland and the Finnish Foundation for 
Cardiovascular Research.  
13. Health, Aging and Body Composition (Health ABC) Study: We also thank Yongmei Liu (Co-PI of Health ABC GWA study grant), who obtained GWA data, 
reviewed the analysis proposal and the manuscript draft.  
The Health ABC study was supported by the Intramural Research Program of the National Institutes of Health, National Institute on Aging and National Institute on Aging 
contracts N01-AG-6-2101, N01-AG-6-2103, and N01-AG-6-2106, NIA grant R01-AG028050, and NINR grant R01-NR012459. Assessment of 25-hydroxyvitamin D 
concentrations was funded by a National Institute on Aging grant, R01-AG029364.  The genome-wide association study was funded by a National Institute on Aging grant, 
R01-AG032098, and genotyping services were provided by the Center for Inherited Disease Research (CIDR). CIDR is fully funded through a federal contract from the 
National Institutes of Health to The Johns Hopkins University (contract number HHSN268200782096C). 
14. Helsinki Birth Cohort Study (HBCS): Genotyping was performed at Sanger Institute which is acknowledged. Helsinki Birth Cohort Study has been supported by grants 
from the Academy of Finland (Grant No. 120386 and 125876 to JGE), the Finnish Diabetes Research Society, Folkhälsan Research Foundation, Finska Läkaresällskapet,Liv 
och Hälsa, Samfundet Folkhälsan, Finska Läkaresällskapet and the Signe and Ane Gyllenberg foundation. 
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15. Hertfordshire cohort study (HCS): Genotyping was in part funded by the British Heart Foundation (grant PG/09/023). The HCS is supported by the Medical Research 
Council of Great Britain; Arthritis Research, UK; the British Heart Foundation; Porticus Foundation; the International Osteoporosis Foundation and the NIHR Biomedical 
Research Unit in Nutrition, University of Southampton, UK; and the NIHR Musculoskeletal Biomedical Research Unit, University of Oxford, UK.  
16. InCHIANTI study: The research leading to the results from InCHIANTI study received funding from European Community’s Seventh Framework Programme 
(FP7/2007-2013) as a Marie Curie Initial Training Networks project (FP7-PEOPLE-ITN-2008) under grant agreement number 238821 (Biology of Liver and Pancreatic 
Development and Disease). 
17. LifeLines Cohort Study: The LifeLines Cohort Study, and generation and management of GWA genotype data for the LifeLines Cohort Study is supported by the 
Netherlands Organization of Scientific Research NWO (grant 175.010.2007.006), the Economic Structure Enhancing Fund (FES) of the Dutch government, the Ministry of 
Economic Affairs, the Ministry of Education, Culture and Science, the Ministry for Health, Welfare and Sports, the Northern Netherlands Collaboration of Provinces (SNN), 
the Province of Groningen, University Medical Center Groningen, the University of Groningen, Dutch Kidney Foundation and Dutch Diabetes Research Foundation. RADB 
has consulted for and received research grants from Abbott. We acknowledge the contribution of all the members of the Lifelines Cohort study (members listed in the 
appendix). 
LifeLines Scientific Protocol Preparation: Rudolf de Boer, Hans Hillege, Melanie van der Klauw, Gerjan Navis, Hans Ormel, Dirkje Postma, Judith Rosmalen, Joris Slaets, 
Ronald P. Stolk, Bruce Wolffenbuttel; LifeLines GWA Working Group: Behrooz Alizadeh, Marike Boezen, Marcel Bruinenberg, Noortje Festen, Lude Franke, Pim van der 
Harst, Gerjan Navis, Dirkje Postma, Harold Snieder, Cisca Wijmenga, Bruce Wolffenbuttel.  
18. Lifestyle- Imune System- Allergy plus environment and genetics study (LISAplus) and German Infant Study on the influence of Nutrition Intervention plus 
environment and genetics (GINIplus): This study was supported by Ludwig-Maximilians-University’s innovative research priority project MC-Health (subproject I). We 
thank all families for participation in the studies; the obstetric units for allowing recruitment, the GINI and LISA study teams for excellent work. 
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19. Ludwigshafen Risk and Cardiovascular Health (LURIC) Study: We extend our appreciation to the participants of the LURIC study; without their collaboration, 
participating in the collaboration would not have been possible. We thank the LURIC study team who were either temporarily or permanently involved in patient recruitment 
as well as sample and data handling, in addition to the laboratory staff at the Ludwigshafen General Hospital and the Universities of Freiburg and Ulm, Germany.  
LURIC has received funding from the 6th Framework Program (integrated project Bloodomics, grant LSHM-CT-2004-503485) and from the 7th Framework Program 
(Atheroremo, grant agreement number 201668 and RiskyCAD, grant agreement number 305739) of the European Union as well as from the INTERREG IV Oberrhein 
Program (Project A28, Genetic mechanisms of cardiovascular diseases) with support from the European Regional Development Fund (ERDF) and the 
Wissenschaftsoffensive TMO. 
20. Males from Genetics of extremely Overweight Young Adults (GOYA): We acknowledge Prof. George Davey Smith from the MRC CAiTE, University of Bristol, 
Bristol, UK who has contributed in conceiving and designing the experiments for this study. We also thank Wellcome Trust (http://www.wellcome.ac.uk/) for providing the 
finances to carry out the study. 
This study was conducted as part of the activities of the Danish Obesity Research Centre (DanORC, www.danorc.dk) and the MRC centre for Causal Analyses in 
Translational Epidemiology (MRC CAiTE). We are thankful to all the volunteers, technicians, research scientists who contributed to the GOYA study. 
21 MRC National Survey of Health & Development (MRC NSHD Birth Cohort): This work was funded by the Medical Research Council (MC_UU_12019/1).  
Genotyping was funded by the British Heart Foundation (grant PG/09/023). We are very grateful to the members of this birth cohort for their continuing interest and 
participation in the study. We would like to acknowledge the Swallow group, UCL, who performed the DNA extractions (Rousseau, et al 2006). 
22. Netherlands Study of Depression and Anxiety (NESDA): The infrastructure for the NESDA study is funded through the Geestkracht programme of the Dutch 
Scientific Organization (ZON-MW, grant number 10-000-1002) and matching funds from participating universities and mental health care organizations. Genotyping in 
NESDA was funded by the Genetic Association Information Network (GAIN) of the Foundation for the US National Institutes of Health. Statistical analyses were carried out 
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on the Genetic Cluster Computer (http://www.geneticcluster.org), which is financially supported by the Netherlands Scientific Organization (NWO 480-05-003) along with a 
supplement from the Dutch Brain Foundation. 
23. Northern Finland Birth Cohort 1986 (NFBC 1986) and Northern Finland Birth Cohort 1966 (NFBC1966): For NFBC1966, the 25-hydroxyvitamin D assays were 
funded by the (MRC; grant G0601653). Genotyping in NFBC1986 was funded by the British Heart Foundation (grant PG/09/023). NFBC programme received financial 
support from the Academy of Finland (project grants 104781, 120315, 129269, 129418, 1114194, 24300796, Center of Excellence in Complex Disease Genetics and 
SALVE), University Hospital Oulu, Biocenter, University of Oulu, Finland (75617), NHLBI grant 5R01HL087679-02 through the STAMPEED program (1RL1MH083268-
01), NIH/NIMH (5R01MH63706:02), ENGAGE project and grant agreement HEALTH-F4-2007-201413, EU FP7 small-scale  focused research collaborative project 
EurHEALTHAgeing 277849, and the Medical Research Council, UK (G0500539, G0600705, G1002319,  PrevMetSyn/SALVE). The DNA extractions, sample quality 
controls, biobank up-keeping and aliquotting was performed in the National Public Health Institute, Biomedicum Helsinki, Finland and supported financially by the Academy 
of Finland and Biocentrum Helsinki. We thank the late Professor Paula Rantakallio (launch of NFBC1966), and Ms Outi Tornwall and Ms Minttu Jussila (DNA biobanking). 
The authors would like to acknowledge the contribution of the late Academian of Science Leena Peltonen.: The research of V.L. is funded in part through the European 
Community's Seventh Framework Programme (FP7/2007-2013), ENGAGE project, grant agreement HEALTH-F4-2007- 201413. The research of I.P. is funded in part 
through the European Community's Seventh Framework Programme (FP7/2007-2013), ENGAGE project, grant agreement HEALTH-F4-2007-201413. 
24. Orkney Complex Disease Study (ORCADES): ORCADES was supported by the Chief Scientist Office of the Scottish Government, the Royal Society, the MRC 
Human Genetics Unit, Arthritis Research UK and the European Union framework program 6 EUROSPAN project (contract no. LSHG-CT-2006-018947). DNA extractions 
were performed at the Wellcome Trust Clinical Research Facility in Edinburgh. We would like to acknowledge the research nurses in Orkney, the administrative team in 
Edinburgh and the people of Orkney. 
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25. Osteoporotic Fractures in Men Study – Sweden (MrOS Sweden): This work was supported by the Swedish Research Council, the Swedish Foundation for Strategic 
Research, the ALF/LUA Research Grant in Gothenburg, the Lundberg Foundation, the Torsten and Ragnar Söderberg's Foundation, the Novo Nordisk Foundation, Magnus 
Bergvall Foundation, Åke Wiberg Foundation, Tore Nilson Foundation, and the Swedish Society for Medical Research. 
26. Prevention of Renal and Vascular Endstage Disease (PREVEND): PREVEND genetics is supported by the Dutch Kidney Foundation (Grant E033), the EU project 
grant GENECURE (FP-6 LSHM CT 2006 037697), the National Institutes of Health (grant LM010098), The Netherlands organisation for health research and development 
(NWO-Groot grant 175.010.2007.006, NWO VENI grant 916.761.70, ZonMw grant 90.700.441), and the Dutch Inter University Cardiology Institute Netherlands (ICIN). 
27. Prospective Investigation of the Vasculature in Uppsala Seniors (PIVUS) and Uppsala Longitudinal Study of Adult Men (ULSAM): PIVUS and ULSAM studies 
were supported by the Swedish Research Council and Knut and Alice Wallenberg Foundation. Genotyping was performed by the SNP Technology Platform at Uppsala 
University, Sweden (http://www.genotyping.se).  
28. Second Northwick Park Heart Study (NPHSII): Genotyping was funded by the British Heart Foundation (grant PG/09/023). NPHSII was supported by the British 
Medical Research Council, the US National Institute of Health (grant NHLBI 33014) and Du Pont Pharma, Wilmington, USA.  JC JA and SEH  are supported by the British 
Heart Foundation (PG08/008). 
29. TRacking Adolescents' Individual Lives Survey (TRAILS): This research is part of the TRacking Adolescents' Individual Lives Survey (TRAILS). Participating 
centers of TRAILS include various departments of the University Medical Center and University of Groningen, the Erasmus University Medical Center Rotterdam, the 
University of Utrecht, the Radboud Medical Center Nijmegen, and the Parnassia Bavo group, all in the Netherlands. TRAILS has been financially supported by various 
grants from the Netherlands Organization for Scientific Research NWO (Medical Research Council program grant GB-MW 940-38-011; ZonMW Brainpower grant 100-001-
004; ZonMw Risk Behavior and Dependence grants 60-60600-97-118; ZonMw Culture and Health grant 261-98-710; Social Sciences Council medium-sized investment 
grants GB-MaGW 480-01-006 and GB-MaGW 480-07-001; Social Sciences Council project grants GB-MaGW 452-04-314 and GB-MaGW 452-06-004; NWO large-sized 
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investment grant 175.010.2003.005; NWO Longitudinal Survey and Panel Funding 481-08-013), the Dutch Ministry of Justice (WODC), the European Science Foundation 
(EuroSTRESS project FP-006), Biobanking and Biomolecular Resources Research Infrastructure BBMRI-NL (CP 32), and the participating universities. We are grateful to 
all adolescents, their parents and teachers who participated in this research and to everyone who worked on this project and made it possible. Statistical analyses were carried 
out on the Genetic Cluster Computer (http://www.geneticcluster.org), which is financially supported by the Netherlands Scientific Organization (NWO 480-05-003) along 
with a supplement from the Dutch Brain Foundation.  
30. Tromsø study: The study was supported by grants from The North Norway Regional Health Authority, the Norwegian Diabetes Association, and the University of 
Tromsø.  
31. Twins UK: The study was funded by the Wellcome Trust; European Community’s Seventh Framework Programme (FP7/2007-2013). The study also receives support 
from the National Institute for Health Research (NIHR)- funded BioResource, Clinical Research Facility and Biomedical Research Centre based at Guy’s & St Thomas’ NHS 
Foundation Trust in partnership with King's College London. Tim Spector is an NIHR senior Investigator and is holder of an ERC Advanced Principal Investigator award. 
SNP Genotyping was performed by The Wellcome Trust Sanger Institute and National Eye Institute via NIH/CIDR.  
32. Whitehall II (WHII) Study: Genotyping was funded by the British Heart Foundation (grant PG/09/023). The Whitehall-II study was supported by the Medical Research 
Council (K013351), the BHF, and the National Institutes of Health (R01HL36310).  
33. Young Finns Study: S.R. was supported by the Academy of Finland Center of Excellence in Complex Disease Genetics (#213506 and #129680), Academy of Finland 
(#251217), the Finnish foundation for Cardiovascular Research and the Sigrid Juselius Foundation. The Young Finns Study has been financially supported by the Academy 
of Finland: grants 134309 (Eye), 126925, 121584, 124282, 129378 (Salve), 117787 (Gendi), and 41071 (Skidi), the Social Insurance Institution of Finland, Kuopio, Tampere 
and Turku University Hospital Medical Funds (grant 9M048 for 9N035 for TeLeht), Juho Vainio Foundation, Paavo Nurmi Foundation, Finnish Foundation of 
Cardiovascular Research and Finnish Cultural Foundation, Tampere Tuberculosis Foundation and Emil Aaltonen Foundation. 
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